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Chapter 1 
 
QSAR 
  
 
8 
Since the Middle Ages the use of substances endowed with medicative activity 
to alleviate suffering had an important role in the popular culture. Scientists 
like Claude Bernard, Louis Pasteur, Robert Koch, Joseph Lister, and Paul 
Ehrlich gave rise to the experimental biomedical research, at the end of the 
19
th century. In particular, Ehrlich introduced the concept of receptor and 
structural modifications of active compounds, opening the way to the modern 
medicinal chemistry. The modern research in the pharmaceutical field made a 
number of new drugs available, sometimes with unpredictable consequences. 
So, there is still a need for more effective and safe drugs. The current 
techniques of rational drug design should help to achieve this goal, and the 
quantitative structure-activity relationship (QSAR) studies rank in this field. 
 
 
1. General introduction 
Much time has passed after the “discovery” of QSAR and its first application, and 
always increasing number of publications have been reported in the literature over 
the years. The following graph reports the number of publications as a result of 
entering the word “QSAR” as a query in SciFinder Scholar. 
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Nevertheless, QSAR still has many open questions, ranging from the identification 
of optimal criteria for selecting descriptors to the ones for selecting the best  
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correlation search, from sick of the most suitable methods for splitting of datasets 
into training and test sets to the estimate of the applicability domain of the QSAR 
model, through the statistical validation of the model itself. 
In this work, a QSAR study was developed as a sequence of several steps, where 
each of them was accurately analyzed so that a very rigorous approach may be 
outlined. Starting from the basic knowledge underpinning the use of classic QSAR, 
the purpose of this study was to implement them with the use of new strategies 
and new protocols, in order to develop highly reliable QSAR models. 
As the subject of the studies presented here, adenosine receptor ligands (in 
particular antagonists) were chosen, since they possess many potential 
therapeutic applications, as it will be recalled later on. The works carried out 
within this thesis will be detailed in chapters 3 and 4, while chapter 5 contains a 
discussion about the overall results obtained in these studies and considerations 
about how, in the future, the development of a QSAR model could be further 
improved. 
 
 
2. The drug discovery process 
Medicinal or pharmaceutical chemistry is a scientific discipline that comprises 
chemistry and pharmacy and that is involved with designing and developing 
pharmaceuticals. Medicinal chemistry includes the identification, synthesis and 
development of new chemical entities suitable for therapeutic use. It also includes 
the study of existing drugs, their biological properties, and their quantitative 
structure-activity relationships. Many disciplines can help medicinal chemistry to 
reach its goal, particularly organic chemistry, biochemistry, computational 
chemistry, pharmacology, molecular biology, statistics, and physical chemistry. 
In medicine, biotechnology and pharmacology, drug discovery is defined as the 
process by which drugs are discovered and/or designed. The main discoveries of 
drugs, in the past, have been made either by identifying the active ingredient 
from traditional remedies or by serendipity. New approaches are instead target-
based. This concept means that the effort is focused in understanding how a given 
disease is controlled at the molecular level and targeting specific biological entities  
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based on this knowledge. The process of drug discovery involves several steps: 
first of all, the identification of candidate compounds, then their synthesis and 
characterization, followed by screening and assays for therapeutic efficacy. Once a 
compound satisfies all the preliminary requirements, it will begin the process of 
drug development prior to clinical trials. 
The first step of drug discovery consists of the identification of new active 
molecules. These are usually called "hit compounds" and are typically found by 
screening a large number of molecules for the biological properties under 
investigation. “Hits” can have natural origins, for example they can be extracted 
from plants, animals, or fungi, otherwise, as often occurs, they can come from 
synthetic sources. The second step of drug discovery involves the synthetic 
modification of “hit compounds” in order to improve their biological properties. For 
this purpose, QSAR plays an important role in finding "lead compounds", which 
should exhibit, for example, higher potency and/or higher selectivity and/or lower 
toxicity depending on the biological system at hand. The final step involves the 
optimization of “lead compounds” making them suitable for subsequent tests. This 
step requires the adjustment of the synthetic route for a large scale production, 
and the preparation of a suitable drug formulation. 
Rational drug design is a modern approach to find drugs by design, based on 
the selected biological target, and starts with the knowledge of specific chemical 
responses in the body. The biological target may be a key molecule involved in a 
particular metabolic or signalling pathway that is specific for a particular disease 
or pathology, for example a receptor. Drug design should not be placed only in the 
first step of the drug discovery process, but at any level of it, as a resource to be 
iteratively used. 
A primary concept of rational drug design is the concept of pharmacophore. A 
pharmacophore was defined for the first time by Paul Ehrlich in 1909 as “a 
molecular framework that carries (phoros) the essential features responsible for a 
drug’s (pharmacon) biological activity” (Ehrlich, 1909). In 1977, this definition 
was reviewed by Peter Gund to “a set of structural features in a molecule that is 
recognized at a receptor site and is responsible for that molecule's biological 
activity” (Gund, 1977). Pharmacophores are used in the modern computational 
chemistry to define the essential features of one or more molecules showing a 
particular biological activity. Usually, pharmacophoric features are expressed in  
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terms of hydrophobic or aromatic moieties in the molecules, as well as hydrogen 
bond acceptor or donor sites, etc. 
Over the last decades, with the advent of computer, cheminformatics has 
always had wider uses and applications in medicinal chemistry. In fact, 
cheminformatics involves the use of computer and informational techniques to 
solve different problems in the field of chemistry. This discipline is also known as 
“chemoinformatics” and “chemical informatics”, and is used in universities and 
pharmaceutical companies to aid the drug discovery process. In this context is 
placed the calculation of parameters related to quantitative structure activity (or 
property) relationships values, used to predict the activity of compounds from 
their structures. 
 
 
3. QSAR: basic concepts 
Quantitative structure-activity relationship (QSAR) is defined as the quantitative 
correlation of the biological properties (pharmacological, toxicological or 
ecological) to the structure of chemical compounds, which allows the prediction of 
the same property (“target” property) of structurally related compounds. 
The history of QSAR has been recently reviewed by Kubinyi (Kubinyi, 2002). In 
that paper, the author pointed out that, although QSAR does not have a clear 
beginning in time, the first documentation about a relationship between molecular 
structures and biological properties appeared in 1863, when A.F.A. Cros et al. 
(University of Strasbourg) observed an increase in the toxicity of alcohols with a 
decrease in water solubility. But the classic QSAR, as still intended nowadays, 
started in the sixties, whit the great contribution of C. Hansch, T. Fujita, S. M. 
Free Jr. and J. W. Wilson, with the following publications: “ς-σ-π Analysis. A 
method for the correlation of biological activity and chemical structure” and “A 
mathematical contribution to structure-activity studies”. In this works, Hansch and 
Fujita estimated the lipophilicity values of aromatic compounds by using the 
constants ς (a reaction constant), σ (the electronic Hammet constant), and π (the 
lipophilicity contribution, referred to the partitioning system octanol/water). These 
authors also introduced the combination of several physicochemical parameters in 
one equation, instead of using one-parameter quantitative models. In an  
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independent work, Free and Wilson formulated the statement that all biological 
activities, in logarithmic scale, are the sum of the biological activity of a reference 
compound plus the group contributions of all substituents attached at various 
position of the reference molecule. In the immediately following years, only few 
parameters were proposed, but very soon a huge number of descriptors were 
introduced, steric parameters, topological indices, etc., so that in the seventies 
criteria for the selection of the variables and motivation for their use in developing 
QSAR models became mandatory. As a consequence, a number of selection 
algorithms were introduced in the subsequent years. But the question was: “which 
models are the best ones?”. The answer is, of course, those models with the best 
fit and best predictive ability. From here, the use of many statistical parameters 
took place for validating the ability of a given model to fit experimental data, such 
as the correlation coefficient, and criteria to test the predictivity, such as the 
leave-one-out or leave-some-out cross validation. In the late seventies and 
eighties the evolution from classic QSAR to 3D-QSAR took place. 3D-QSAR 
considers the three-dimensional properties of compounds, calculated for a huge 
number of points over a grid enveloping them. A typical example is CoMFA, in 
which all molecules having the same mechanism of action are rationally aligned 
and superimposed, according to orientation rules that ensures good probability of 
identifying the pharmacophoric properties. As a limit of its high analytical power, 
the main pitfall of CoMFA is the assumption of a single 3D conformation, beside 
the problem that compounds can present more than one conformation. This lead 
to the 4D-QSAR approaches, which allows for multiple representations of a 
molecule, also accounting for different stereoisomers and different protonation 
states. Very recently, a further expansion is going from the multiple ligand 
representation of the 4D-QSAR towards the 5D-QSAR, which allows for multiple 
target representations. But, before thinking about “hyperspace”, as Kubinyi said, a 
brief and easy explanation about the basis on which QSAR is founded will be given 
in the following section, that includes molecular representations, chemical 
databases, QSAR equations, correlation estimates, etc. 
In general, a molecule is the smallest particle of a pure chemical substance that 
still retains its composition and chemical properties. In chemistry and molecular 
sciences, a molecule is a sufficiently stable, electrically neutral entity composed of 
two or more atoms.  
 
13  
There are several kinds of molecular representations. One of them is the 
chemical formula, which gives information about the exact number of atoms 
that compose a molecule. The chemical formula also identifies each type of 
chemical element by its element symbol. Molecular geometry or molecular 
structure is the three dimensional arrangement of the atoms that constitute a 
molecule. Molecular geometry of a compound is directly related to several of its 
properties, including its reactivity, polarity, physic state, color, magnetism, and so 
on up to its biological activity. The relative position of each atoms is determined 
by the chemical bonds through which one atom is connected to its neighborings. 
The molecular geometry can either be defined by the Cartesian coordinates of the 
atoms in a proper reference axis system or by the bond lengths, the bond angles 
between two adjacent bonds, and the torsion angles of three consecutive bonds 
(the so-called Z-matrix). Molecules can also be represented by means of 
molecular  descriptors, that are defined as numerical values of the chemical 
features derived on the basis of their chemical constitution, topology, geometry, 
and inherent wavefunction, so they can have a bi- or three-dimensional character. 
Molecular descriptors will be detailed in the next section.  
Modeling chemical structures or mimicking the behavior of molecules is the main 
task of computational techniques that are generally indicated as molecular 
modeling. It is used in computational chemistry and computational biology for 
the investigation of molecular systems ranging from small chemical compounds to 
large biological molecules, allowing their description at the atomic level. Within 
the field of molecular modeling, the molecular mechanics refers to the use of 
classical (Newtonian) mechanics to describe the physical basis behind the models. 
The model typically describe atoms as a point charge and mass, while the 
chemical bonds are represented by spring-like interactions between neighboring 
atoms and van der Waals forces. The electrostatic interactions are calculated on 
the basis of Coulomb's law, and coordinates in the Cartesian space are usually 
assigned to each atom. 
Molecular mechanics approaches are widely used in molecular structure 
refinement. The overall expression is known as potential energy function and 
represents a thermodynamic quantity: the internal energy (E). Lower internal 
energy values are expected to correspond to more stable molecules, so that the 
energy minimization techniques supply suitable methods for identifying 
plausible atom configurations of a molecule.  
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E = Ebonds + Eangle + Edihedral + Enon-bonded 
Enon-bonded = Eelectrostatic + Evan der Waals 
This function represents the molecular potential energy as a sum of energy terms 
that describe the deviation of bond lengths, bond angles and torsion angles away 
from equilibrium values, plus terms for non-bonded pairs of atoms describing Van 
der Waals and electrostatic interactions. The set of parameters consisting of 
equilibrium bond lengths, bond angles, partial charge values, force constants and 
Van der Waals parameters are collectively known as force-field. Moreover, a 
molecular dynamics simulation describes the behavior of a system as a 
function of time. By solving the Newton's equation of motion, F = ma, a molecular 
dynamics simulation leads to trajectories of the molecule in space and time. So, 
while the energy minimization technique is used to obtain a static picture of a 
molecule, molecular dynamics provides information about the dynamic processes, 
also considering the effects of temperature. It also allows sampling a huge 
number of molecular configurations that may be exploited for calculating other 
thermodynamic properties. 
A collection of molecules, comprising their structures and related data of interest, 
can be used to form a chemical database, which is a database specifically 
designed to store chemical, physico-chemical, biological or pharmacological 
information. Within them, databases may be subdivided into families or “clusters” 
of molecules based on similarities between each other. 
A single unambiguous definition of molecular similarity does not exist. As an 
example, it can be mentioned here that two molecules might be considered more 
similar, for example, if their difference in molecular weights is lower with respect 
to others. But similarity can also be defined on the basis of moieties and 
substituents present in the molecules, perhaps linked to a common template. In 
recent years the concept has been be defined through several different criteria 
that lead to the development of algorithms enabling quantitative estimate of 
molecular similarity/dissimilarity (see for example Flower, 1998 and Ruiz et al., 
2005 and references therein). 
Just in order to provide a short overview about the more common mathematical 
a s p e c t s  o f  Q S A R ,  i t  i s  h e r e  r e m i n d e d  t h a t  a  linear equation is an equation  
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involving only the algebraic sum of products of constants and variables (taken to 
their first power). The name of “linear” equation is because it describes a straight 
line in a Cartesian reference system. The simplest linear equation used to 
illustrate the QSAR models in this work is the so-called slope-intercept form: 
y = M·x + F 
where M is the slope of the straight line and F is the intercept with the y axis. In 
the specific case of a QSAR equation, the independent variable x is represented by 
molecular descriptors, while y is the biological target, such as, for example, the 
pKi value. 
In the probability theory and statistics, the correlation expresses the linear 
relationship between two variables, and the correlation coefficient measures the 
amount of such a relationship. The correlation coefficient R may range from -1 to 
1: the correlation is 1 in the case of an increasing linear relationship, −1 in the 
case of a decreasing linear relationship. It takes intermediate values in all other 
cases, indicating the degree of linear dependence between the variables. The 
closer the correlation coefficient R is to either −1 or 1, the stronger the correlation 
between the variables, while the correlation is 0 when the variables are fully 
independent. It turns out that the use of R
2, as the correlation coefficient is more 
convenient as it ranges between 0 and 1. 
The regression analysis is a general statistical method where the mean of one 
or more random variables is predicted on the basis of other (measured) random 
variables. In QSAR, the correlation represents the results of the (multi)linear 
regression between the biological property of interest y (the so-called “target” 
property) and some selected molecular descriptors di. The goal of regression is to 
describe a data set as accurately as possible. This is a primary requirement for a 
Q S A R  m o d e l  t o  b e  a b l e  t o  p e r f o r m  a n  accurate prediction (from Latin præ- 
“before” plus dicere “to say”) of the target property value, since the main goal is 
to predict property values using one of the previously derived and stored 
correlations.  
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4. CODESSA: an example of QSAR software 
CODESSA (COmprehensive DEscriptors for Structural and Statistical Analysis) “is 
a chemical multi-purpose Quantitative Structure-Activity and Structure-Property 
(QSAR/QSPR) statistical analysis and predictions program”.  
 
A typical working session begins with the creation of an input text file, an example 
of which is illustrated in Fig. 1. 
 
 
 
 
 
 
 
Fig. 1 The input file includes the name of the molecules in the first column, the 
full-length path which allows the program to find the mol file related to each 
molecule in the second column, and the target property in the third column. 
 
 
Such an input file allows loading the structures and activity data into the program, 
afterwards data can be rearranged, for example by splitting them into a training 
set (TR) and a test set (TS). 
 
The following step is the calculation of a large number (> 450) of molecular 
descriptors, which are based on the geometrical and/or electronic structure of the 
molecules. Various structural features of the compound give rise to the numerical 
values of the descriptors. The molecular descriptors calculated in CODESSA are 
grouped into several classes, named constitutional, topological, geometrical, and 
electrostatic. A brief outline of each class of molecular descriptors is given below. 
Constitutional descriptors. These simple bi-dimensional descriptors reflect the 
molecular composition of the compound without using the geometry or electronic 
structure of the molecule. Examples of constitutional descriptors are: 
- Number of atoms 
- Absolute and relative numbers of C, H, O, S, N, F, Cl, Br, I, P atoms 
- Number of bonds 
 
STRNAME MOLPATHS "PROPVALUES:pKi" 
F1    C:\Flavomol\F1.mol   5.5016894462104 
F2    C:\Flavomol\F2.mol   5.91721462968355 
F3    C:\Flavomol\F3.mol   6.43889861635094 
F4    C:\Flavomol\F4.mol   6.12609840213554 
F5    C:\Flavomol\F5.mol   6.49894073778225  
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- Absolute and relative numbers of single, double, triple and aromatic bonds 
- Number of rings, number of rings divided by the number of atoms 
- Number of benzene rings, number of benzene rings divided by the number of 
atoms 
- Etc. 
 
Topological descriptors (also known as topological indices) describe the atomic 
connectivity in the molecule and are calculated by means of more or less complex 
mathematical formulas. An example of a topological descriptor is the Wiener index 
(Wiener, 1947), that can be expressed in the terms of the distance matrix. This 
distance matrix is a square matrix (NSA x NSA), and the entries dij correspond to 
the number of bonds in the shortest path connecting the pair of atoms i and j. The 
Wiener index W equals to the half-sum of all distance matrix entries: 
 
∑ =
SA N
j i
ij d
) , ( 2
1
W  
 
Geometrical descriptors. These descriptors require the three-dimensional 
coordinates of the atoms in the given molecule. Examples of geometrical 
descriptors are: 
- Shadow indices. By the orientation of the molecule in the space along the axes 
of inertia, they reflect the areas of the shadows S1, S2 and S3 of the molecule as 
projected on the XY, YZ and XZ planes. 
- Molecular volume. The molecular volume is calculated by applying 3D grid of 
cubes in the parallelepiped box with the dimensions Xmax,  Ymax  and  Zmax 
standing around the molecule. 
- Etc. 
 
Electrostatic descriptors. These descriptors reflect characteristics of the charge 
distribution of the molecule.  The empirical partial charges in the molecule are 
calculated using the approach proposed  by Zefirov (Zefirov et al., 1987). This 
method is based on the Sanderson electronegativity scale and uses the concept 
which represents the molecular electronegativity as a geometric mean of atomic 
electronegativities. Examples of electrostatic descriptors are: 
- Minimum and maximum partial charges in the molecule  
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- Minimum and maximum partial charges for particular types of atoms (C, N, O 
etc.) 
- Charged partial surface area descriptors, encoding features responsible for polar 
interactions between molecules, in terms of the whole surface area of the 
molecule and in terms of functional group portions 
- Etc. 
 
Once descriptors have been calculated, the subsequent step is developing a 
QSPR/QSAR model. To do this, CODESSA allows the user to perform a correlation 
analysis using the heuristic method, on the basis of compounds belonging to the 
TR. This method accomplishes an automatic preselection of descriptors on the 
basis of discarding: 
1) Missing values, that is descriptors for which values are not available for every 
structure in the data in question 
2) Bad values, that is descriptors having a constant value for all structures in the 
data set. 
After this preselection of descriptors, the heuristic stepwise procedure which tests 
all possible one-parameter regression models and removes insignificant 
descriptors. All the remaining descriptors are then listed in decreasing order 
according to the correlation coefficient of the related one-parameter correlation 
equation. 
As a next step, the program calculates the pair correlation matrix of descriptors 
eliminating highly correlated ones. This step is done using the following pairs: (a) 
the first descriptor with each of the remaining descriptors, the second descriptor 
with each of the remaining descriptors, etc. All two-parameter regression 
equations with the remaining descriptors are then developed and ranked by the 
regression correlation coefficient R
2. A stepwise addition of further descriptors is 
performed until reaching the maximum number of descriptor, a parameter the 
user can directly set, to find the best multi-parameter regression models with the 
optimum values of statistical parameters (highest values of R
2, the crossvalidated 
R
2, and the F-value). 
As a final result, the program generates lists of the best correlations found, in 
terms of R
2 and F-values. An example of such a list of correlations is illustrated in 
Fig. 2. 
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Once the correlation equations (models) are found, an internal validation may be 
carried out, by means of a leave-one-out cross-validation (the button “R2(CV)” in 
Fig. 2). The crossvalidated (CV) correlation coefficient is calculated as follows: 
1) For each experimental data point multi-linear regression is recalculated with 
the same descriptors of the selected model but for the data set without this point, 
2) then the obtained regression equation is used to predict the value of this data 
point, 
3) finally the obtained array of predicted data points is linearly correlated with the 
array of experimental data points and the correlation coefficient of the last 
correlation is the crossvalidated correlation coefficient. The crossvalidated 
correlation coefficient, named R
2-CV or q
2, is essentially considered as a 
characteristic of the predictive power of the correlation equation. The role of this 
statistical parameter will be more accurately discussed in the next chapters. 
 
 
Fig. 2 In the first two columns the R
2 and F-values of each correlation are 
provided, respectively. The third column reports the number of descriptors 
involved in each equation, and the target property (pKi). 
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Fig. 3 In the first two columns the calculated ad the experimental biological 
values are provided, respectively. The third column reports the prediction error, 
as a difference between the two previous values and the code of the 
corresponding compound. 
 
 
Once a previously derived model has been submitted to this internal validation, it 
can be used for a prediction, since predicting property values for the compounds 
which belongs to the TS is often the final goal of a QSAR/QSPR treatment. Upon 
prediction, CODESSA prints out the calculated (i.e. predicted) and experimental 
property values, as illustrated in Fig. 3. 
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Chapter 2 
 
Adenosine and adenosine receptors  
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Adenosine has many other names. Some synonyms that one can find around 
the internet are Adenine Riboside, Adenocor, Adenocard, and Adenoscan. Its 
formula is C10H13N5O4. This compound, with a mol mass of 267.24 g, contains 
44.94% Carbon, 4.90% Hydrogen, 26.21% Nitrogen, and 23.95% Oxygen. It 
should be stored at 4°C. The melting point for Adenosine is about 235°C, and 
the boiling point is not easily available. The nucleoside also has a CAS number 
of 58-61-7. It has a density of 580 kg/m
3 , and a pH value of around 5-7. 
Adenosine can be easily manufactured as a byproduct of RNA by being 
chemically extracted from the RNA compound. It is also made in the body, so 
it's very widely distributed in nature. 
 
 
1. Adenosine receptors and GPCRs 
Adenosine (Fig. 1) is essential for the proper functioning of every cell in the body. 
In fact, adenosine is present in all cell types, with a basal concentration in the nM 
- μM range (DeNinno, 1998). 
O
OH OH
O H
N
N N
N
NH2
 
Fig. 1. Adenosine 
 
 
Adenosine receptors are members of the purinergic (P1) family of G-protein 
coupled receptors (GPCRs) and have been classified into four subtypes: A1, A2A, 
A2B, and A3 receptors, mainly on the basis of their high (A1, A2A) or low (A2B, A3) 
affinity for adenosine itself (Fredholm et al., 2001). 
G protein-coupled receptors are generally made up of 450-600 amino acid, with 
molecular weights usually ranging from 40 to 50 kDa. The GPCR structure is 
characterized by seven transmembrane α-helices connected to each other by  
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extra- and intracellular loops (Schoneberg, et al., 1999). The seven hydrophobic 
fragments are around 20-28 amino acid length and are connected by three short 
extracellular and three intracellular loops. 
G proteins are heterotrimers made up of by three different subunits: α, β, and γ. 
The  α subunit is unique for each G protein. It shows high affinity for guanine 
nucleotides and possesses intrinsic GTPase activity; receptors catalyze the 
exchange of GDP by GTP in this subunit. The β and γ subunits are tightly 
associated in a βγ complex. This complex is required for an efficient regulation of 
the α subunit activity. Nowadays, G proteins are distinguished in approximately 20 
different subtypes. The G proteins may be grouped into the following main 
classes: Gs (stimulating adenylate cyclase and Ca
2+ channels), Gi (inhibiting 
adenylate cyclase, stimulating K
+ channels), Gt or transducins (stimulating cGMP 
phosphodiesterase), G0 (stimulating K
+ channels, inhibiting Ca
2+ channels), and Gq 
(activating phospholipase C) (Hepler and Gilman, 1992). Fig. 2 are summarizes 
the coupling of the adenosine receptors to G proteins. 
 
 
Fig. 2 Coupling of the adenosine receptors to G proteins 
 
The coupling between receptors and G proteins promoted by agonists leads to the 
activation of intracellular effectors, such as enzymes and ion channels. These 
effectors substantially amplify the production of second messengers feeding into  
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the signal cascade. This cascade may culminate in the physiological response of 
the cell to the extracellular stimulus (Marinissen and Gutkind, 2001). 
 
 
2. Adenosine A1 receptor 
The adenosine A1 receptor is expressed in the central nervous system (CNS), 
especially in the cortex, cerebellum and thalamus. Although in a smaller extent, A1 
receptor can also be found peripherally in heart, kidney, epididymal fat and testis. 
A1 receptor is coupled with Gi protein and inhibits adenylate cyclase, leading to a 
decrease in cellular cAMP levels. Fig. 2 illustrates the snake model of the 
adenosine A1 receptor (Beukers et al., 1999). 
 
 
Fig. 2 The snake model of the adenosine A1 receptors 
 
 
The adenosine A1 receptor also couples with phospholipase C (PLC), which, upon 
activation, converts phosphatidylinositol-4,5-biphosphate (PIP2) into diacylglycerol 
(DAG) and inositol triphosphate (IP3). IP3 elevates levels of Ca
++, which can 
stimulate a number of different biologic pathways. In contrast, a depletion of Ca
++ 
from IP3-sensitive pools may promote Ca
++  influx from extracellular source. 
Furthermore, stimulation of adenosine A1 receptors can activate several types of  
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potassium channels, described principally in cardiac muscle and neurons (Olah 
and Stiles,1995). 
 
 
3. Adenosine A2A and A2B receptors 
Two receptor subclasses exist for adenosine A2 receptors, named A2A and A2B, 
which are grouped on the base of their affinity for adenosine and its derivatives. 
One of these derivatives is 2-(4-methoxyphenylamino)-adenosine (CV1674), 
showing a high affinity for A2A receptors, and a low affinity for A2B  receptors. 
Moreover, [
3H]CGS21680 and [
125I]PAPA-APEC can also be used to distinguish 
between these receptors in binding studies, since these compounds show affinity 
only for A2A receptors (Hide et al., 1992). The snake models of adenosine A2A and 
A2B receptors (Beukers et al., 1999) are illustrated in Figs. 3A and 3B, 
respectively. 
 
 
A 
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Fig. 3 The snake models of adenosine A2A (A) and A2B (B) receptors 
 
 
In the brain, adenosine A2A receptor distribution is limited to striatum, nucleus 
accumbens and olfactory tubercle. In contrast, adenosine A2B receptors are 
distributed diffusely throughout the brain. A2A receptors are modestly expressed in 
heart, lungs, thymus, and epididymal fat, while A2B receptors are reached in 
caecum, large intestine, and urinary bladder, and at a lower extent in lungs. 
These receptor subclasses are both coupled with Gs proteins and activate 
adenylate cyclase, leading to an increase in cellular cAMP levels. In turn, cAMP 
modulates the activity of cAMP-dependent protein kinase A (PKA), which 
phosphorylates several protein targets. Adenosine A2B receptors coupling to 
different G proteins giving rise to differ e n t  s i g n a l  p a t h w a y s  h a v e  a l s o  b e e n  
reported. They can activate Ca
++ channels via Gs protein, and phospholipase C via 
Gq protein (Palmer and Stiles, 1995). 
 
 
4. Adenosine A3 receptor 
The youngest member of the adenosine receptor family, the A3 receptor, was 
discovered in 1991. Its characteristics is that alkylxanthine derivatives, 
traditionally used to classify events mediated by adenosine receptors, bind very 
poorly to this receptor. High levels of A3 receptor have been found in lungs and  
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liver, while lower levels have been found in aorta and brain. Fig. 4 illustrates the 
snake model of the adenosine A3 receptor (Beukers et al., 1999). 
 
 
Fig. 4 The snake model of the adenosine A3 receptor 
 
 
These receptors are coupled with Gi proteins and inhibit adenylate cyclase, leading 
to a decrease in cellular cAMP levels. Moreover, they can stimulate phospholipase 
C, leading to an enhancement of intracellular levels of Ca
++, and phospholipase D. 
Coupling to ion channels has also been observed (van Muijlwijk-Koezen et al., 
2001). 
 
 
5. Functions of adenosine receptors 
Adenosine receptors are widely distributed in most species and mediate several 
biological effects. The physiological responses to adenosine are complex and 
depend on which receptor subtype is activated. The regulation of the energy 
supply/demand balance of cells by adenosine is commonly proposed to be 
mediated by A1  and A2 receptor subtypes. An increase in oxygen demand 
(exercise) or a decrease in oxygen supply (ischaemia, hypoxia) result in a 
distortion of the energy balance of tissue (Bruns, 1991). In fact, in each 
pathologic condition involving a reduction of oxygen availability, the aerobic 
metabolism decreases and the anaerobic metabolism increases, leading to a rapid  
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depletion of the pool of ATP and other molecules with high energetic content. 
Hydrolysis of ATP induces an intracellular accumulation of adenosine, which is 
released in large amounts into the extracellular compartment by its specific 
nucleoside transporter. This phenomenon may involve endothelial cells, 
erythrocytes, platelets and every kind of cell damaged by ischemic injury. Thus, 
adenosine can diffuse from the cell where it acts locally, and may both decrease 
oxygen demand (A1) and increase oxygen supply (A2), so reinstating the proper 
energy balance. 
In the cardiovascular system, the activation of adenosine A1 receptors induces 
cardiac depression through negative chronotropic, dromotropic and inotropic 
effects. So, the heart rate results to be slowed via adenosine A1 receptors located 
on sinoatrial and atrioventricular nodes. This effect, in combination with 
vasodilatation mediated by adenosine A2A and A3 receptors through the relaxation 
of the arterioles and most of the vessels, induces a decrease in blood pressure. 
These vasodilator effects of A2A receptors are mediated, at least in part, by the 
increase of intracellular cAMP levels, although it has been suggested that 
activation of ATP-dependent K
+ channels may also play an important role in 
mediating this phenomenon
 (Olsson and Pearson, 1990). Furthermore, adenosine 
receptors activation can have antiarrhytmic effects (A1), decrease neutrophilic 
function (A2A), stimulate nitric oxide production by vascular endothelial cells (A2A) 
and inhibit platelet aggregation (A2A). Vasodilatation also seems to be induced 
with the contribution of the vascular adenosine A2B receptors, in both smooth 
muscle and endothelium. The adenosine A3 receptors are thought to induce 
cardioprotection, due to their role in ischemic preconditioning. The involvement of 
adenosine in this preconditioning phenomenon follows from the early work on 
mechanical preconditioning. Brief periods of mechanically induced ischemia 
protect tissues from a subsequent longer period of ischemia. It has been reported 
that adenosine levels rose sharply during this short preconditioning episodes. 
Furthermore, adenosine has a wide range of effects in the CNS. It modulates the 
intercellular communication in the brain by affecting neuronal activity. This 
includes inhibition of neurotransmitter release via the adenosine A1 receptors and 
enhancing of neurotransmitter release via the adenosine A2A receptors, particularly 
in the peripheral nervous system, for what concerns these last receptor subtypes. 
Thus, adenosine is described by the term “neuromodulator”, to point out its 
regulatory role. Adenosine can also exert behavioral effects: by interacting with  
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adenosine A1 or A2A receptors, it is involved in the regulation of sleep and in its 
sedative, anticonvulsant, anxiolytic, nociceptive and locomotor depressant effects 
(DeNinno, 1998). Adenosine A1 receptor mediates antinociceptive effects by 
modulation of primary afferent transmission to spinal neurons of the dorsal horn. 
From studies of pain in animal models has emerged that administration of 
adenosine analogues via supraspinal, spinal or systemic routes induced 
antinociceptive effects (Dickerson et al, 2000). In the periphery, A1 receptor 
activation still produces pain suppression, but this action is less important than 
the one produced through the A2 receptors, which the activation of produces pain 
enhancement (Sawinok, 1998). The depressant effect on locomotion is possibly 
mediated by the adenosine A3 receptor as well (Jacobson et al, 1993). In the 
brain, adenosine A2A receptors are primarily found in the striatum where they are 
co-localized with D2 dopamine receptors. In the kidney a biphasic modulation of 
renin release takes place. In fact, vasoconstriction and inhibition of renin secretion 
result from activation of adenosine A1 receptor, whereas opposite effects can be 
obtained by activation of the adenosine A2A receptors. The adenosine A1 receptor 
in the kidney also decreases the glomerular filtration rate and inhibit the 
neurotransmitter release. Adenosine A1 receptors are also localized in adipocytes. 
In these cells, they inhibit the lipolysis (maintenance of the body weight) and 
increase insulin sensitivity. 
A l l  r e c e p t o r  s u b t y p e s  s e e m  a l s o  t o  b e  i m p o r t a n t  i n  t h e  i m m u n e  s y s t e m .  T h e  
adenosine A1 and/or A2A receptors suppress the immune system by inhibition of 
lymphocyte proliferation and modulation of neutrophilic function. Also the 
adenosine A2B and A3 receptors may play an important role in allergic and 
inflammatory responses. In rat, activation of adenosine A3 receptors induces mast 
cell degranulation, with subsequent facilitation of the release of allergic mediators, 
including histamine. 
Adenosine receptors are also involved in many other processes in the body. For 
example, in the liver the adenosine A1 and A2A receptors regulate hepatic blood 
flow and stimulate gluconeogenesis. In the stomach, the same receptors inhibit 
gastric secretion. Low-level activation of adenosine A3 receptors may induce cell 
protection, since this opposes apoptotic cell death in several cases, and in some 
particular cells the cellular antioxidant defense system is promoted (DeNinno, 
1998).  
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6. Potential therapeutic applications 
of adenosine receptor ligands 
The wide distribution of adenosine receptors throughout the body reflects a broad 
therapeutic potential for adenosine agonists, antagonists, and maybe also 
allosteric modulators. The therapeutic possibilities involving the adenosine 
receptors have been recently reviewed (Fredholm, 2003; Müller, 2003) and are 
briefly summarized below. 
Adenosine A1 receptor is found in the spinal cord and shows antinociceptive 
properties. In the kidney, its blockade, for example by caffeine, is known to 
increase urine production and sodium elimination. Blockade of A1 receptor can also 
lead to an increased lipid metabolism, with consequent potentialities in the 
treatment of obesity. Adenosine receptor appears also involved in other metabolic 
d i s o r d e rs ,  s uc h  a s  t y pe  I I  di a b et es .  A g ai n,  i t  i s  k n o w n  t h at  a d e n os i n e p r o t e c t s  
organs, including the heart and the brain, from ischemic injury, by involving 
several receptor subtypes. Adenosine also causes bronchoconstriction, but only 
after challenge with an allergen and in asthmatic subjects. The known adenosine 
receptor antagonist theophylline, in fact, has antiasthmatic properties. On the 
other hand, A3 antagonists appear to reduce intraocular pressure, and their use 
has been proposed for the treatment of glaucoma. 
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Chapter 3 
 
QSAR Study on Thiazole and Thiadiazole 
Analogues as Antagonists for the Adenosine A1 
and A3 Receptors 
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Abstract 
 
Thiazole and thiadiazoles analogues have been recently proposed as a novel 
promising class of adenosine A1 and A3 receptors antagonists. When opportunely 
modified they show selectivity towards A1  or A3  receptors and this results in a 
variety of therapeutic potentialities of these ligands. In this work, a QSAR study 
on thiazole and thiadiazole analogues, analyzed as antagonists for the adenosine 
A1 and A3 receptors, was carried out. In order to develop reliable models, the 
attention was focused on the possible pitfalls of each step of the QSAR process 
and approached every stage following accurate procedures. The treatment of the 
datasets by using the CODESSA software lead to QSAR equations based on three- 
and four-descriptors for the adenosine A1 and A3 receptor ligands, respectively. 
The obtained models allowed us to understand the main structural features which 
strongly correlate with the target property. 
 
 
Keywords 
 
QSAR, model validation, adenosine receptors, thiazole and thiadiazole analogues. 
 
 
1. Introduction 
All the adenosine receptors belong to the G-protein coupled receptors (GPCRs) 
family. The classification of adenosine receptors is based on their different 
sensitivities for agonist and antagonist compounds. So far, four subtypes of 
adenosine receptors are known, named A1, A2A,  A2B, and A3 (Fredholm et al., 
2001). Over the years, much attention has been focused towards the development 
of ligands for the adenosine receptors, since they show a variety of therapeutic 
potentialities. The implications of adenosine receptors and their ligands in several 
potential therapeutic areas have been recently reviewed (Fredholm, 2003). In 
particular, adenosine A1 receptor antagonists appear to be involved in pain, kidney 
disorders, such as chronic renal failure, and metabolic disorders, such as obesity. 
Adenosine A3 receptor antagonists appear to play a role in inflammatory pain, 
glaucoma, cerebral ischemia and asthma (Fredholm, 2003; Müller, 2003). Several 
classes of adenosine receptor antagonists are known. In the recent years, thiazole  
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and thiadiazoles analogues have been proposed as a novel promising class of A1 
and A3 receptor antagonists. In fact, they can be opportunely modified in order to 
improve selectivity towards adenosine A1 (van Muijlwijk-Koezen et al., 2001; van 
Tilburg et al., 2002) or A3 (Jung et al., 2004) receptors. 
QSAR (Quantitative Structure-Activity Relationships) is a technique used to 
establish a correlation between chemical structures and a target property, such as 
the affinity towards a given receptor. In this approach, chemical features are 
represented by a set of numerical descriptors, which are then used for an estimate 
of the biological activities. In a rational drug design process QSAR is an important 
step, since it allows to have an early prediction of the biological activity of newly 
designed molecules. For this reason, any QSAR study should lead to statistically 
robust models able to give accurate and reliable predictions of the biological 
activities of the compounds. QSAR studies are afforded as a sequence of different 
steps. The first step implies the database preparation and involves the choice of 
the structural and biological data, the construction of the dataset, and its splitting 
into training and test sets. Such a splitting is required for proper validation of the 
model developed thanks to the QSAR analysis, as described below in the text. The 
second step consists of data analysis and QSAR equation development. It includes 
the calculation and selection of molecular descriptors, the choice of the correlation 
method between independent variables (descriptors) and dependent variables 
(biological activities). The QSAR model validation is the third step. This is, 
probably, the most delicate step and different authors generally face it using 
different approaches. Finally, the fourth step is the definition of the domain of 
applicability of the QSAR model obtained. This step is required to ensure that the 
QSAR model obtained has a good predictive power.  
In this chapter a QSAR (Quantitative Structure-Activity Relationships) study 
carried out on thiazole and thiadiazole analogues as antagonists for the adenosine 
A1 and A3 receptors is described. In particular, the attention was focused on the 
possible limitations of each step of the QSAR process and approached every stage 
with an accurate procedure, in order to develop reliable QSAR models. 
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2. Materials and methods 
2.1. Statistical parameters 
In the next section the statistical parameters used during the development and 
validation of the QSAR models will be discussed. They are listed below. R
2 is the 
correlation coefficient, calculate for both the training (TR) and test (TS) sets; q
2 is 
the mean value of leave-one-out cross validated R
2; F and s
2 are the F-value and 
the standard deviation of the regression, respectively, and they are derived from 
the following formulae (Selassie, 2003): 
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where yi is an observation, n is the number of compounds, and v is the number of 
variables. 
 
2.2. Dataset preparation 
As recently suggested by Cronin and Shultz (Cronin and Schultz, 2003), highly 
homogeneous biological data are required to develop a QSAR model with good 
predictive capability. High quality biological data are ideally measured by the 
same protocol, within the same laboratory and by the same operator. The dataset 
analyzed here was built by using data collected from the literature. All the data 
came from the same author. A further problem which any analyst of structure-
activity relationships has to face with consists of the need of knowing (or plausibly 
hypothesizing) the pharmacophoric conformations of the analyzed molecules. 
Ionization states and tautomeric equilibria are related to the pH of the 
experimental assay; it also contributes in increasing the difficulty about selecting 
proper conformations. Undertaking some assumptions is often mandatory: they 
will be supported by the model validation step. The amide tautomeric forms were 
considered as the more probable ones. The initial molecular geometries were  
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drawn on the basis of indications reported in literature (van Muijlwijk-Koezen et 
al., 2001, Jung et al., 2004). They were then optimized according to the protocol 
described below. Three compounds for each dataset (the most active compound, 
the less active one, and a molecule with an intermediate activity value) were 
submitted to Molecular Dynamics simulations (MD) in order to collect a quite large 
ensemble of structures: the conformations characterized by lower energy values 
subsequently underwent to energy minimization, according to a commonly 
followed protocol. For each molecule the best conformer was so selected as the 
more stable one. The superimposition of these structures in their optimal 
conformations gave rise to a common “template”. All the remaining molecules 
were then built in this conformation and subjected in turn to energy minimization, 
in order to fully relax them. The computational details are described below. 
All the initial geometries were built by using the Insight molecular modeling 
program (Accelrys Inc., San Diego, CA), then the molecules were solvated with a 
layer of 5 Å, and the pH was fixed to the physiological value of 7.4. The structures 
initially selected for accurate geometry optimization were first energy minimized in 
order to prepare them to MD simulations. All the energy minimizations were 
carried out by a Molecular Mechanics (MM) approach implemented in the Discover 
program (Accelrys Inc., San Diego, CA) which also implements the MD simulations 
algorithm used in this work. The cff91 force-field was selected and a distance-
dependent dielectric function (ε=1r), was used both for MM and MD calculations. 
Molecular Dynamics simulations were carried out on all the molecules selected for 
accurate geometry optimization. Each system was initially heated to 300 K, 
equilibration was reached after 5 ps simulation. Structures were collected by 
sampling the trajectory after a 50 ps simulation. The collected structures showing 
lower energy values were then further relaxed by a second step of energy 
minimization, that was carried out with 1000 steps of steepest descent, followed 
by conjugated gradient until potential energy rms < 0.05 Kcal/mol. All the 
calculations were run on Silicon Graphics (SGI) R10000 197 MHz. 
All the affinity data about the thiazole and thiadiazole derivatives of interest were 
collected from the literature (see the two QSAR models described in this chapter 
for respective references). The pKi, coming from the logarithmic transformation of 
the Ki values, obtained from radio-ligand binding data on adenosine A1 and A3 
receptors, were respectively chosen as target property. 
We split each dataset into a training set (TR) and a test set (TS) using a stratified 
random selection method. TS included at least five compounds, whose activities  
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reflected the whole range of activities of the TR, in order to get the TS as much 
representative as possible of the whole data set (Golbraikh and Tropsha, 2002). 
According to this stratified random method, compounds were arranged in 
increasing order of pKi values, the so obtained list was spilt in bins, then within 
each bin a given number of compounds was randomly selected. The latter 
molecules were included in the TS. 
 
2.3. Data analysis and QSAR equation development 
All the minimized structures, as well as their pKi values, were processed by the 
CODESSA program (http://www.codessa-pro.com), which automatically calculated 
a number of molecular descriptors for each molecule. In CODESSA the molecular 
descriptors are grouped into different families: among them constitutional, 
topological, geometrical and electrostatic types are included. Constitutional and 
topological descriptors only require 2D molecular structure information. 
Geometrical descriptors instead are based on the 3D coordinates, and electrostatic 
ones reflect the charge distribution of the molecules. At this level plausible 
molecular conformations are required. The protocol we used to select the best 
descriptors and models is summarized below. 
1) 1) Each one of the TR sets (both for adenosine A1 and A3 receptors) was split 
into several disjoined couples of subclasses (X1 and Y1, X2 and Y2,…. Xn and Yn) so 
that X are used as training sets and Y are used as test sets. In general, many 
criteria can be adopted for the generation of the X and Y subclasses. In the cases 
analyzed here, five couples of X/Y were generated, were every X contained 2/3 of 
the compounds belonging to the initial TR and every Y included 1/3 of the 
compounds chosen with a stratified random selection. 
2) For each X subclass, correlation equations with 1, 2,…NDmax descriptors 
( m a x i m u m  n u m b e r  o f  d e s c r i p t o r s )  w e r e  c a l c u l a t e d  b y  m e a n s  o f  t h e  h e u r i s t i c  
correlation, which is automatically accomplished by the program. The heuristic 
pre-selection method, accurately described in the CODESSA reference manual, is 
based on a stepwise procedure which, first of all, discards all descriptors with 
missing values, or the ones characterized by a poor degree of variation between 
different structures. A further exclusion of descriptors highly inter-correlated is 
also carried out. At this level the use of some control parameters for the heuristic 
pre-selection of descriptors is required in order to avoid over-correlation. A QSAR  
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model is valid and stable when the ratio of number of observations (compounds) 
and number of independent variables (descriptors) is at least 5:1 (Cronin and 
Schultz, 2003). Moreover, we set the control parameters a little lower than the 
ones taken by default by the program, in order to further decrease the acceptable 
inter-correlation allowed between descriptors. Maximum number of descriptors, 
NDmax=5; one-parameter significance criteria, R
2
min=0.01; high intercorrelation 
level, rfull=0.90; significant intercorrelation level, rsig=0.70; one-parameter t-test 
for significance, t1=0.1; multi-parameter t-test for significance, t2=3, branching 
criteria,  NS=3. Based on the pre-selected descriptors, the program provides 
several basic correlation equations. The remained descriptors are then added by 
the program to provide the best correlation equations. 
3) Descriptors involved in the best models resulted for each subclass X were 
applied to the other subclasses X by means of a Multi Linear Regression (MLR) 
treatment, to identify all the diagnostic descriptors. 
4) All the correlation equations so obtained for every subclass X were used in turn 
to estimate pKi values of the respective subclass Y. 
5) All the best QSAR equations developed for all the couples X/Y and involving 1, 
2, …, NDmax descriptors were selected on the basis of the q
2 calculated from X and 
R
2 calculated from Y. 
6) Descriptors included in the equations selected as the best ones, were applied to 
the whole TR by means of a multi linear regression. This resulted in a set of 
correlation equations, based on 1, 2, …, NDmax descriptors, which were used for 
the prediction of the TS. 
7) Several QSAR models developed for the class of thiazole and thiadiazole 
analogues on both adenosine A1 and A3 receptors turned out to be validated 
according to the above mentioned criteria. Each equation contained a different 
number of descriptors. In general, every additional descriptor improves the 
statistical quality of the model, but it also increases its complexity. In this work, 
the selection of the best model was performed, by considering the variations in 
both  q
2 and R
2 of the TS as the number of involved descriptors increased 
(Katritzky et al., 2004). The point beyond which no significant improvements are 
observed is so identified; the corresponding model is selected as the best one. 
 
  
 
42  
2.4. QSAR model validation 
As reported by Golbraikh and Tropsha (Golbraikh and Tropsha, 2002), one of the 
most used criteria for an internal estimate of the predictive ability of a QSAR 
model is q
2. Nevertheless these authors pointed out that a high value of q
2 is not 
sufficient for assessing a high predictive power of the model. In order to 
accurately estimate the predictive ability of the model, further conditions over the 
validation parameters of the test set are required. The statistical analysis, for 
validating the models obtained here, was performed according to their 
suggestions. First of all, QSAR models were submitted to the so-called “internal 
validation” (check on the R
2 and q
2 over the TR). Only the models with q
2>0.5 
were selected for the so-called “external validation” (check on the R
2 and other 
parameters over the TS). Going briefly through the above mentioned additional 
validation parameters will allow to better understand how their use improve the 
validation step. In the plot of experimental versus predicted activities, the 
obtained regression line (y = ax + b) is characterized by a correlation coefficient 
R
2. In an ideal QSAR model, the slope of the line (a) is 1, the intercept with y axis 
(b) is 0 and R
2 (varying between 0 and 1) is 1. R
2 calculated on the TS must be ≥ 
0.6. When the regression line is forced to pass through the origin of the axes 
(intercept set to 0), its slope (k) should be as close as possible to 1, and close to 
the slope of the actual regression line as well. 0.85 ≤ k ≤ 1.15 is suggested as an 
acceptable range. Finally, the correlation coefficient R0
2 of the regression line 
forced through the origin should be as close as possible to the value of R
2, so that 
(R
2 - R0
2)/ R
2 < 0.1. Summarizing, the validation criterion adopted for the QSAR 
model described here states that all the following conditions have to be 
simultaneously satisfied: q
2 > 0.5, for the TR, R
2 > 0.6, 0.85 ≤ k ≤ 1.15, and (R
2 - 
R0
2)/ R
2 < 0.1, for the TS. 
 
2.5. Chemical domain of model validity 
The predictive ability of the model is usually tested by checking it over an external 
test set. But how chemically different can be the external set from the dataset 
which the model has been developed on? This point is still under discussion, and 
several authors face it in different ways, for example by developing special 
algorithms (Golbraikh and Tropsha, 2000), or by comparison of performances 
using prediction sets selected in different surroundings of the chemical space 
(Szántai-Kis et al., 2003). Here the assumption that the chemical space where the  
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developed models do have predictive ability belongs to the chemical class of the 
thiazole and thiadiazole analogues analyzed is made. Moreover, a further 
restriction was introduced by analyzing the descriptor space defined by descriptors 
involved in the models. For each descriptor involved in every QSAR equation the 
range between minimum and maximum numerical value of the relevant numerical 
contribution was considered. The intersection of all the ranges for each one of the 
involved descriptors gave the descriptor space of that equation. When those 
descriptors are calculated for the molecules which biological properties have to be 
predicted for, the numerical value of all the descriptors involved in the model 
equations must fall into the related interval; if not the corresponding compound 
has to be discarded as an outlier. Inside this domain of applicability, the model 
possesses interpolation ability that is rigorously validated, while outside this 
domain it may have extrapolation ability, which goodness is not supported by 
statistics. 
 
 
3. Results and Discussion 
3.1. QSAR study of adenosine A1 receptor ligands 
In the work described in this chapter, a dataset of 34 thiazole and thiadiazole 
analogues was analyzed. Their structures and affinity values at the rat adenosine 
A1 receptor were collected from the article of van Muijlwijk-Koezen et al., 2001 
and from the article of van Tilburg et al., 2001. The above dataset was split into a 
TR, including 27 compounds, and a TS, including 7 compounds (Table 1). On the 
basis of the TR, several QSAR equations were built, each one containing a 
different number of descriptors. The model selected as the best one included the 
smallest number of descriptors together with the largest values of q
2 and R
2. 
Based on these criteria, the following equation was derived, based on three 
descriptors: 
 
pKi = 17.28 (± 1.60) + 155.1 (± 17.38) MPCN + 3.86 (± 0.99) ZXS/ZXR                 
+ 2.12 (± 1.11) PP/D
2 
 
Internal validation (over the training set) provided the following statistics: 
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R
2=0.8122, F=33.15, s
2=0.1463, q
2=0.7418 
 
External validation (over the test set) provided the following statistics: 
 
R
2=0.7856, k=0.9996, R0
2=0.7855, (R
2-R0
2)/R
2=0.0001273 
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Figure 1. Experimental versus calculated pKi values based on the three-
descriptors correlation equation for the adenosine A1 receptor, concerning TR 
(A) and TS (B). 
 
 
The differences between experimental and calculated biological data are reported 
f o r  b o t h  T R  ( T a b l e  2 )  a n d  T S  ( T a b l e  3 ) .  R e g r e s s i o n  l i n e s  o b t a i n e d  b y  p l o t t i n g  
experimental versus predicted pKi values and related statistical data for TR and TS 
are shown in Figure 1. The applicability domain of the QSAR model to the 
adenosine A1 receptor ligands, considered as the intersection of the numerical 
contributions of descriptors involved in the correlation equation, is reported in 
Table 4.  
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Table 1. The structural features of thiazole and thiadiazole analogues, their affinity values at 
the adenosine A1 receptors, and their splitting into TR and TS. 
 
Compound X  Y  R  pKi TR/TS 
1 (LUF5433)  CH CH  4-OCH3C6H4 7.119186  TS 
2 (LUF5417)  N CH  4-OCH3C6H4 7.49485  TR 
3  CH N  C6H5 5.769551  TR 
4  CH N  4-ClC6H4 6.69897  TR 
5  CH N  4-IC6H4 5.619789  TR 
6  CH N  4-CH3C6H4 5.79588  TR 
7  CH N  4-OCH3C6H4 5.49485  TS 
8  CH N  3,4-diClC6H3 5.79588  TS 
9  CH N  3-ClC6H4 5.769551  TR 
10  CH N  4-NO2C6H4 5.823909  TR 
11  CH N  4-OCH(CH3)2C6H4 5.236572  TR 
12  CH N  cyclopentyl  6.036212  TR 
13  N CH  C6H5 7.508638  TR 
14  N CH  4-ClC6H4 7.387216  TS 
15  N CH  4-CH3C6H4 7.522879  TR 
16  N CH  4-OHC6H4 8.136677  TR 
17  N CH  4-OCH2CO2HC6H4 7  TR 
18  N CH  cyclohexyl  5.853872  TR 
19  N CH  (trans) 4-OCH3-cyclohexyl 7.49485  TR 
20  N CH  (cis) 4-OCH3-cyclohexyl 6.958607  TR 
21  N CH (trans) 4-OH-cyclohexyl  7.69897  TS 
22  N CH  (cis) 4-OH-cyclohexyl  7.376751  TR 
23  N CH  NHC6H5 6  TR 
24  CH N  NHC6H5 6.031517  TS 
25  CH CH  C6H5 7.408935  TR 
26  CH CH  3-ClC6H4 7.065502  TR 
27  CH CH  4-BrC6H4 7.481486  TS 
28  CH CH  4-ClC6H4 7.744727  TR 
29  CH CH  4-NO2C6H4 7.657577  TR 
30  CH CH  4-CH3C6H4 7.443697  TR 
31  CH CH  4-C(CH3)3C6H4 5.866461  TR 
32  CH CH  4-CF3C6H4 6.782516  TR 
33  CH CH  3,4-diClC6H3 7.229148  TR 
34  CH CH  2,4-diClC6H3 7.236572  TR 
 
 
Y
S N
X
N H O
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Table 2. Comparison between experimental and calculated pKi values at the adenosine A1 
receptor, and evaluation of the minimum, means and max error for TR. 
 
 
Compound   Experimental pKi Calculated  pKi Error 
2 (LUF5417)  7.49485 7.4996 0.0047 
3  5.769551 5.6833  -0.0862 
4  6.69897 6.3246  -0.3743 
5  5.619789 6.1965  0.5767 
6  5.79588 5.9439 0.1481 
9  5.769551 5.5798  -0.1897 
10  5.823909 5.9993  0.1754 
11  5.236572 5.5393  0.3028 
12  6.036212 5.4739  -0.5623 
13  7.508638 7.471  -0.0377 
15  7.522879 7.3915  -0.1314 
16  8.136677 8.2797  0.1431 
17  7 7.1159  0.1159 
18  5.853872 6.7945  0.9406 
19  7.49485 6.7724  -0.7225 
20  6.958607 6.8088  -0.1498 
22  7.376751 7.148  -0.2288 
23  6 5.9648  -0.0352 
25  7.408935 7.5174  0.1084 
26  7.065502 7.3067  0.2412 
28  7.744727 7.5243  -0.2204 
29  7.657577 7.1086  -0.5489 
30  7.443697 7.3246  -0.1191 
31  5.866461 6.5061  0.6396 
32  6.782516 6.7828  0.0002 
33  7.229148 7.3023  0.0732 
34  7.236572 7.173  -0.0636 
 
 
Minimum absolute error = 0.0002, mean absolute error = 0.2570, maximum absolute error = 
0.9406  
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Table 3. Comparison between experimental and calculated pKi values at the adenosine A1 
receptor and evaluation of the min, means and max error for TS. 
 
Compound   Experimental pKi Calculated  pKi Error 
1 (LUF5433)  7.119186 6.8936  -0.2256 
7  5.49485 5.9575 0.4626 
8  5.79588 6.1499 0.3540 
14  7.387216 7.9052  0.5180 
21  7.69897 7.2719  -0.4270 
24  6.031517 5.6649  -0.3666 
27  7.481486 7.1797  -0.3018 
 
Minimum absolute error = 0.2256, mean absolute error = 0.3749, maximum absolute error = 
0.5180 
 
 
The importance of each descriptor was evaluated by looking at the t-test value. 
The first descriptor included in the equation, Minimum Partial Charge on a N atom 
(MPCN) (t=8.9251), is comprised, within the CODESSA background, among the 
electrostatic descriptors empirically calculated. It has positive sign in the QSAR 
equation: an increasing numerical contribution corresponds to an increase in pKi. 
It reflects the importance of the second N atom on the central ring and accounts 
for the observed trend in affinity for the adenosine A1 receptor: thiadiazoles > 
thiazoles > thiazolopyridines (Y=N). The presence of a substituent able to 
increase the partial charge, such as an electron-donor group at the position R, is 
so suggested. The second descriptor, ZX Shadow/ZX Rectangle (ZXS/ZXR) 
(t=3.9037), is comprised, within the CODESSA background, among the so-called 
geometrical ones. It suggests that an aromatic group R, like a phenyl ring, 
eventually bearing small substituents, should be preferred to aliphatic cycles. Its 
numerical contribution is especially increased with the size of the substituent R, 
while the nature of the central ring slightly do affect it. Finally, the third 
descriptor,  Polarity Parameter/Square Distance (PP/D
2) (t=1.9023), also of 
electrostatic type, supports the importance of an electron-donor group substituent 
at position R. It is only affected by the nature of the R substituent; when R is an 
electron-donor group, this descriptor contributes with a higher numerical 
contribution. The results of this QSAR study are in agreement with the classical  
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structure-activity relationships reported by IJzerman and coworkers (Muijlwijk-
Koezen et al., 2001; van Tilburg et al., 2001). 
 
 
Table 4. Minimum and maximum numerical contributions of the three descriptors involved in 
the correlation equation for the adenosine A1 receptor. 
 
 
MPCN ZXS/ZXR  PP/D
2 
Min  -9.23E-02 5.60E-01 5.90E-03 
Max  -8.14E-02 8.33E-01 2.69E-01 
 
 
3.2. QSAR study of adenosine A3 receptor ligands 
32 Thiazole and thiadiazole analogues and their affinity values at human 
adenosine A3 receptor were collected from the article of Jung et al., 2004. The 
whole dataset was split into a TR made up of 26 compounds and a TS made up of 
6 compounds (Table 5). Based on the TR, several QSAR equations were 
constructed, each one containing a different number of descriptors. The model 
including the smallest number of descriptors but leading to the largest increase in 
q
2 and R
2 was selected as the best one. The following equation was derived, based 
on four descriptors: 
 
pKi = -6.17 (± 2.47) + 17296 (± 260) HACA-2 / TMSA + 22.73 (± 4.44) RNH + 
46.56 (± 10.83) MPCS – 0.382 (± 0.00935) WNSA-3 
 
Internal validation provided the following statistics: 
 
R
2=0.6996, F=12.23, s
2=0.3121, q
2=0.5478 
 
External validation provided the following statistics: 
 
R
2=0.6755, k=1.061, R0
2=0.6719, (R
2-R0
2)/R
2=0.005329 
 
The differences between experimental and calculated biological data are reported 
f o r  b o t h  T R  ( T a b l e  6 )  a n d  T S  ( T a b l e  7 ) .  R e g r e s s i o n  l i n e s  o b t a i n e d  b y  p l o t t i n g   
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experimental versus predicted pKi values and related statistical data for TR and TS 
are shown in Figure 2. 
 
 
Table 5. The structural features of thiazole and thiadiazole analogues, their affinity values at 
the adenosine A3 receptors, and their splitting into TR and TS. 
 
                     (2, 35-59, 61-65)              (60) 
 
Compound X Y  R  pKi TR/TS 
2 (LUF5417)  N H  4-OCH3C6H4  7.086186 TR 
35  CH H  CH3 7.737549  TR 
36  CH H  (CH3)3CO 5.29243  TR 
37  CH H  NCCH2 6.69037  TR 
38  CH 4-Cl  CH3 7.293282  TR 
39  CH 4-Cl  C6H5CH2 7  TS 
40  CH 4-CH3O CH3 8.522879  TR 
41  CH 3-CH3O CH3 8.387216  TR 
42  CH 2-CH3O CH3 7.086186  TR 
43  CH 4-CH3O CF3  6.275724 TR 
44  CH 4-CH3O CH3CH2 8.619789  TR 
45  CH 4-CH3O CH3CH2CH2  8.107905 TR 
46  CH 4-CH3O (CH3)2CH 7.787812  TR 
47  CH 4-CH3O NCCH2 7.614394  TR 
48  CH 4-CH3O (CH3)3C 7.496209  TR 
49  CH 4-CH3O (CH3)3O 5.486782  TS 
50  CH 4-CH3O C6H5  7.542118 TS 
51  CH 4-CH3O C6H5CH2  7.847712 TS 
52  CH 4-CH3O C6H5CH2CH2  7.536107 TR 
53  CH 4-CH3O  p-CH3OC6H4CH2 5.935542  TR 
54  CH 4-CH3O  p-CH3OC6H4CH2CH2 7.543634  TR 
55  CH 4-CH3O (C6H5)2CH 6.279014  TR 
56  CH 4-CH3O (C6H5)2CHCH2  6.39794 TR 
57  CH 4-CH3O 2-furan 7.501689  TR 
58  CH 4-CH3O thiophene-2-CH2 7.490797  TS 
59  CH 4-CH3O 2-thiophene 7.159267  TR 
60       6.428291  TR 
61  N H  CH3 8.638272  TS 
62  N H  C6H5CH2  7.102373 TR 
63  N 4-CH3O CH3  9.102373 TR 
64  N 4-CH3O C6H5CH2  7.623423 TR 
65  N 4-CH3O CH3CH2  8.946922 TR 
N
S X
N
H
O
R
Y
N
S N
N
H
CH3
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Table 6. Comparison between experimental and calculated pKi values at the adenosine A3 
receptor, and evaluation of the minimum, means and max error for TR. 
 
Compound   Experimental pKi Calculated  pKi Error 
2 (LUF5417)  7.0862 7.3135  0.2273 
35  7.7375 7.6463  -0.0913 
36  5.2924 5.59  0.2976 
37  6.6904 7.881  1.1906 
38  7.2933 7.3082  0.0149 
40  8.5229 7.8778  -0.6451 
41  8.3872 7.8858  -0.5014 
42  7.0862 7.4747  0.3886 
43  6.2757 5.9299  -0.3459 
44  8.6198 8.0885  -0.5313 
45  8.1079 8.0029  -0.1050 
46  7.7878 7.4277  -0.3601 
47  7.6144 8.1726  0.5582 
48  7.4962 7.6177  0.1215 
52  7.5361 7.3555  -0.1807 
53  5.9355 7.2413  1.3057 
54  7.5436 7.8876  0.3439 
55  6.279 6.1321  -0.1469 
56  6.3979 6.5775  0.1795 
57  7.5017 6.6302  -0.8715 
59  7.1593 6.6667  -0.4926 
60  6.4283 6.8145  0.3862 
62  7.1024 6.9922  -0.1101 
63  9.1024 8.781  -0.3214 
64  7.6234 7.6632  0.0398 
65  8.9469 8.5963  -0.3506 
 
Minimum absolute error = 0.0149, mean absolute error = 0.3888, maximum absolute error = 
1.3057 
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Table 7. Comparison between experimental and calculated pKi values at the adenosine A3 
receptor and evaluation of the min, means and max error for TS. 
 
Compound   Experimental pKi Calculated  pKi Error 
39  7 6.5455  -0.4545 
49  5.4868 6.0622  0.5754 
50  7.5421 6.8329  -0.7092 
51  7.8477 6.9584  -0.8893 
58  7.4908 6.4519  -1.0389 
61  8.6383 8.5722  -0.0661 
 
Minimum absolute error = 0.0661, mean absolute error = 0.6222, maximum absolute error = 
1.0389 
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Figure 2. Experimental versus calculated pKi values based on the four-
descriptors correlation equation for the adenosine A3 receptor, concerning TR 
(A) and TS (B). 
 
 
The applicability domain of the QSAR model to the adenosine A3 receptor ligands 
is reported in Table 8. The importance of each descriptor was evaluated by looking 
at the t-test value. The first descriptor included in the equation is HACA-2/TMSA 
(t=6.6464), where HACA-2 means total charge weighted HACA, HACA means 
Hydrogen-Acceptors Charged surface Area, and TMSA means Total Molecular 
Surface Area. This descriptors is not affected by any particular moiety in the 
molecule, it reflects instead the behavior of the whole molecule. It is an 
electrostatic descriptor which emphasizes that the ligand should interact with the 
adenosine A3 receptor by means of H-bonds, particularly it should be able to  
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accept H-bonds from the receptor. The second descriptor, the constitutional 
descriptor  Relative number of H atoms (RNH) (t=5.1102), suggests the 
importance of small alkyl groups at the position R, since they increase the 
numerical contribution of this descriptors more than aromatic rings. It is only 
affected by the amide substituent, since it shows the highest variability. The 
Minimum Partial Charge on a S atom (MPCS) is the third descriptor (t=4.2999) 
and belongs to the electrostatic family of descriptors. Its is strongly affected by 
the nature of the central ring, and it is possible to establish a well defined 
threshold value between thiazoles and thiadiazoles. The presence of a second N 
atom in the ring, near the S atom, probably affects its partial charge, because of 
its electro-negativity. This descriptor suggests that thiadiazole should be preferred 
to thiazole derivatives. WNSA-3 is the fourth descriptor (t=-3.3122), where 
WNSA-3 means total surface weighted PNSA, and PNSA means Partial Negative 
Surface Area. This electrostatic descriptor reflects both the negative charge and 
the total molecular surface properties. It is characterized by a negative sign in the 
QSAR equation, and shows the importance of small molecule endowed with an 
only weak negative charge. The obtained results are in agreement with the 
structure-based studies on ligand-receptor interactions recently described in the 
paper of Jung et al., 2004. 
 
 
Table 8. Minimum and maximum numerical contributions of the three descriptors involved in 
the correlation equation for the adenosine A3 receptor. 
 
 
HACA-2/TMSA RNH  MPCS  WNSA-3 
Min  1.00E-03 3.10E-01  -4.17E-04  -1.04E+01 
Max  3.49E-03 4.74E-01  -4.22E-02  -2.83E+00 
 
 
4. Conclusions 
In the study described above the attention was focused on accurately affording 
each step that gives rise to the development of a QSAR model. The efforts were 
aimed at increasing the reliability of QSAR models for thiazole and thiadiazole 
derivatives under analysis, acting as antagonists for the adenosine A1 and A3 
receptors. The analysis of the results obtained shows that the models developed  
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are in agreement with previous structure-activity relationships and structure-
based studies described in the literature. Moreover, the results appear to supply 
useful suggestions for the design of new ligands acting as antagonists for the 
adenosine A1 and/or A3 r e c e p t o r s .  M o r e  i n  d e t a i l ,  w e  e x p e c t  t h a t  a  t h i a d i a z o l e  
derivative with an aromatic substituent may enhance the affinity for the adenosine 
A1 receptor, especially when the aromatic ring brings an electron-donor group. On 
the contrary, a small thiadiazole analogue, able to accept hydrogen bonds and 
bearing a small, non-polar, alkyl substituent at the position R should possess a 
high affinity for the adenosine A3 receptor. 
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Abstract 
 
A dynamic protocol for training set selection has been applied to classic QSAR in 
order to obtain predictive models with high robustness when estimating properties 
of interest for molecules belonging to proper virtual libraries. The attention was 
focused in well defining the chemical space of validity for the models (in turn 
defining the limits of the virtual library to be screened), so that proper 
training/test set pairs were selected as parts of wider databases. This approach 
may turn out to give a great help in the process of lead optimization. The study 
described here has been performed on 539 adenosine A3 receptor antagonists 
belonging to all the chemical classes known up to date. The local models obtained 
from each class gave better results than the overall model, so suggesting the 
importance of appropriate selection criteria for the training set in relation to a well 
defined test set, leading in turn to a precise definition of the chemical space 
validity of each one of the local models considered. Interpolation and 
extrapolation abilities of the obtained models were also estimated, allowing 
accurate analysis of the role of QSAR in the “lead finding” and “lead optimization” 
steps of drug discovery. 
 
 
Keywords 
 
QSAR, training set selection, adenosine A3 receptor antagonists 
 
 
1. Introduction 
Adenosine A3 receptor, together with A1, A2A and A2B, belongs to the superfamily of 
the G-protein coupled receptors (GPCRs) (Fredholm et al., 2001). The many 
possible roles, played by the adenosine receptor ligands in a number of potential 
therapeutic areas, have been recently reviewed (Fredholm, 2003). Particularly, 
adenosine A3 receptor antagonists appear to be involved in inflammatory pain, 
glaucoma, cerebral ischemia and asthma (Müller, 2003). For this reason, a variety 
of potent and selective ligands for the adenosine receptors have been proposed 
over the years.  
 
57
Among the huge number of quantitative structure-activity relationship (QSAR) 
studies available in the literature, several ones deal with adenosine receptor 
ligands. Most studies, no matter the application field, share various features, 
mostly regarding the protocols involved in developing the QSAR models of 
interest. Such protocols consist of the a common sequence of steps, that is 
recalled below, in order to better clarify the novelty of the work proposed here. 
The step list may be summarized as follows: (1) collecting a dataset made up of 
compounds with a specific target property; (2) splitting it into fully disjoined 
training set (TR) / test set (TS) pairs, sometime according to automatic selection 
algorithms; (3) developing the QSAR model on the basis of the TR, generally with 
the aid of suitable software which calculates and correlates various molecular 
descriptors; (4) validating the obtained model by using it to predict the target 
property on the TS, and estimating its performance by means of statistical 
parameters. The literature reports many criteria and principles aimed at increasing 
the goodness, i.e. the predictive ability, of QSAR models. This is commonly done 
by trying to develop a model on the basis of a TR which contains a great number 
of diverse compounds, under the hypothesis that an increasing number of 
molecules is capable of supplying more information. The observed decreasing 
goodness of the models when the molecular diversity increases is intended as a 
limitation, almost a pitfall, of QSAR itself. For this reason, the trend leads to add 
more and more molecules to the TR. 
In this chapter, several experiments are reported showing that small and targeted 
TRs can work better than the large ones and may results in models endowed of a 
higher predictive ability within focused virtual libraries. In order to well define the 
chemical space of validity for the models (in turn defining the limits of a virtual 
library to be screened), a “dynamic” procedure is illustrated for selecting, within a 
large database, only the most suitable molecules to be included in the TRs. That is 
achieved focusing on the molecules belonging to the test sets that will be used for 
validation. Such an approach turns out to be greatly helpful in correctly defining 
the virtual library were predictions are reliable. 
 
 
2. Results and Discussion 
Several QSAR models were developed, working with a very large initial database 
of known molecules that contains 539 compounds, acting as antagonists for the  
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adenosine A3 receptors. Data regarding these molecules were obtained from 
Moro’s paper (Moro et al., 2005a) and references therein. 
Tables illustrating the chemical features of the 539 molecules under investigation 
and their affinity values (Ki) at the adenosine A3 receptor are reported in Appendix 
A of Supporting Information. The first approach consisted of building a QSAR 
model by exploiting the whole database previously collected (“full” model). The 
database was split into a TR containing 499 compounds and a TS containing 40 
compounds. A first TS was selected by taking the same molecules belonging to 
the Moro’s TS, in order to be able of comparing the results of this work with 
Moro’s ones, when strongly increasing the initial database. The correlation found 
was quite poor (R
2 = 0.4335 on the TR). Subsequently the whole dataset was split 
into 14 chemically homogeneous classes (A-P), according to the protocol 
described in the experimental section. “Local” QSAR models were developed 
within each one of the above classes. Single smaller TSs, exploited in developing 
each “local” model, were taken from the initial TS (“full” model). The differences 
between experimental and calculated pKi values, obtained when developing the 
“local” models, are reported for both subTR and TS in Appendix B of Supporting 
Information, as well as a table indicating the descriptor space of each equation, as 
described in Borghini et al., 2005 and briefly summarized below. The chemical 
space where the model validity is ensured is defined by the intersection of the 
ranges (max and min) of the values taken by each one of the descriptors involved 
in the equations defining the model itself. 
 
2.1. Local models – “Lead optimization” 
Once a lead compound has been identified, its structure must be systematically 
modified in order to improve its characteristics until new molecules with improved 
properties are obtained. The aim of the “Lead optimization” process is, for 
example, to maximize the therapeutic index and minimize side effects, leading to 
new substances that are more effective than already known compounds. In order 
to achieve this purpose a medicinal chemist has usually to deal with datasets 
containing a relatively small number of already known compounds, often taken 
from the literature. In planning changes to be introduced on a well established 
molecular template, the medicinal chemist looks for already known compounds 
that must be structurally close to the ones he is designing, forbearing to consider 
the activities of structurally different compounds. In this way, the chemist can 
approximately obtain a more or less rough estimate of the target property values  
 
59
that will be presented by the newly designed molecules. In this research it has 
been observed that splitting a huge database of compounds with a specific target 
property, which contains quite diverse molecules, into smaller datasets, only 
containing molecules with high structural similarity, allows retaining the most 
relevant information content. The information lost after leaving out many diverse 
molecules does not give, on the other hand, its negative contribution to the 
performance of the local model developed. Moreover, as mentioned before, the 
information exploited by medicinal chemists is usually taken from the literature. 
The use of structurally focused datasets in comparison to large and structurally 
diverse ones turns out to be more profitable, since the data analyzed are taken 
from a small number of authors (ideally only one), thus reducing the extent of 
experimental error affecting the information content. It may be useful to mention 
that differences in Ki values of a ligand measured by different research groups are 
found, not only when binding assays are performed by using different 
radioligands, but also in experiments where the same radioligand and the same 
cell line are used (see, for example, data from “ligand binding constants” in 
http://www.gpcr.org). 
To give an idea about how large such differences may be, two examples are 
reported below: (1) DPCPX shows pKi = 6.70 at the human adenosine A3 receptor 
when tested in displacement assays of [
125I]AB-MECA in CHO cells (Patel et al., 
1997) and pKi  = 5.40 when tested in displacement assays of [
3H]NECA in the 
same cell line;
 (Klotz et al., 1998) (2) CGS15943 shows pKi = 8.10 when tested in 
displacement assays of [
125I]AB-MECA in CHO cells
 (Patel et al., 1997) and pKi = 
7.29 when tested in displacement assays of [
3H]NECA in the same cell line (Klotz 
et al., 1998). 
Among other considerations, the above data give a feeling about the level of 
accuracy we hare dealing with in predictions aimed at drug design. Finally, each 
molecule belonging to the TS of each one of the local models reported below, was 
checked out in order to see whether it was included or not into the descriptor 
space, i.e., whether it felt or not into the applicability domain of related model. It 
allowed verifying if the property prediction for such a molecule had to be 
considered interpolated or extrapolated by the model at hand. The description of 
the treatment of each chemically focused class of known molecules follows. 
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A) Flavonoid derivatives 
36 Flavonoid derivatives were collected from Karton et al., 1996 and from Ji et al., 
1996. Compounds 4, 13 and 34 were included in the TS. Among the remaining 33 
molecules a targeted subTR made up of 15 compounds was selected according to 
the proposed protocol. On the basis of such subTR, the following three-descriptor 
equation was derived: 
 
pKi = -15.28 (±5.94) + 25.47 (±7.04) ZXS/ZXR – 41.56 (±15.02) MPCC             
– 0.158 (±0.061) HASA-2 
 
R
2=0.6948; F= 8.3463; n=15; s
2=0.175 
 
Descriptors involved in this model are ZX shadow/ZX rectangle (ZXS/ZXR), a 
geometrical descriptor depending on the overall shape of the molecule and its 
projection on the ZX axis, the minimum partial charge for a C atom (MPCC), an 
electrostatic descriptor reflecting the charge distribution of the molecule, and 
HASA-2, i.e. the total charge weighted hydrogen-acceptors surface area, an 
electrostatic descriptor which emphasizes the importance of hydrogen bonding in 
the receptor-ligand interaction. All the TS molecules were included within the 
descriptor space. 
 
 
B) Pyridine and 1,4-dihydropyridine derivatives 
111 Pyridine and 1,4-dihydropyridine derivatives were collected from van Rhee et 
al., 1996, from Jiang et al., 1996, from Li et al., 1998 and from Li et al., 1999. 
Compounds 131 and 141 were included in the TS. Among the remaining 109 
molecules a targeted subTR made up of 6 compounds was selected according to 
the proposed protocol. On the basis of such subTR, the following one-descriptor 
equation was derived: 
 
pKi = 10.07 (±0.74) – 0.825 (±0.221) NO 
 
R
2=0.7770; F= 13.9381; n=6; s
2=0.0651 
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The descriptor involved is the constitutional number of O atoms (NO). All the TS 
molecules were included within the descriptor space. 
 
 
C) Triazoloquinazoline derivatives 
45 Triazoloquinazoline derivatives were collected from Kim et al., 1996 and from 
Kim et al., 1998. Compounds 150 and 182 were included in the TS. Among the 
remaining 43 molecules a targeted subTR made up of 6 compounds was selected 
according to the proposed protocol. On the basis of such subTR, the following one-
descriptor equation was derived: 
 
pKi = 18.42 (± 2.78) + 216.88 (± 56.51) MPCN 
 
R2=0.7865; F=14.7324; n=6; s
2=0.0190 
 
The descriptor involved is the electrostatic Maximum partial charge for a N atom 
(MPCN). The two TS molecules fell outside the descriptor space. 
 
 
D) Imidazo[2,1-i]purin-5-one derivatives 
6 Imidazo[2,1-i]purin-5-one derivatives were collected from Müller et al., 2002. 
Compound 195 was included in the TS. The remaining 5 molecules supplied the 
TR. The following one-descriptor equation was derived: 
 
pKi = 11.50 (± 1.51) – 9.96 (± 3.00) ACIC(1) 
 
R
2=0.7854; F=10.9765; n=5; s
2=0.3305 
 
The Average complementary information content (order 1) (ACIC(1)) is the 
descriptor involved, belonging to the topological indices class. The TS molecule 
was included within the descriptor space. 
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E) Pyrazolo triazolo pyrimidine derivatives 
104 Pyrazolo triazolo pyrimidine  derivatives were collected from Moro et al., 
2005b. Compounds 244, 301 and 302 were included in the TS. Among the 
remaining 101 molecules a targeted subTR made up of 13 compounds was 
selected according to the proposed protocol. On the basis of such subTR, the 
following two-descriptor equation was derived: 
 
pKi = 6.48 (± 5.71) + 114.07 (±18.30) RNBR – 0.180 (± 0.130) CIC(2) 
 
R
2=0.8139; F= 21.8670; n=13; s
2=0.2321 
 
The constitutional relative number of benzene rings (RNBR) and the topological 
Complementary information content (order 2) (CIC(2)) are the descriptors 
involved. Molecule 301 did not fall within the descriptor space. 
 
 
F) 1,2,4-Triazolo[4,3-a]quinoxalin-1-one derivatives 
34 1,2,4-Triazolo[4,3-a]quinoxalin-1-one derivatives were collected from Colotta 
et al., 2000a. Compounds 304, 310, 327 and 336 were included in the TS. Within 
the philosophy of the proposed protocol, this dataset was further split in the 
following two subsets: 
 
F1) Compounds 304, 310 were taken as TS1. On the basis of 20 molecules 
selected for the relevant TR1, for whose prediction the following three-descriptor 
equation was derived: 
 
pKi = 11.97 (± 2.17) + 1.62 (± 0.31) NDB – 1.92 (± 0.51) NN                           
– 2.57e-04 (± 1.95e-04) WI 
 
R
2=0.6784; F=11.2479; n=20; s
2=0.3008 
 
The number of double bonds (NDB), the number of N atoms (NN) and the Wiener 
index (WI) are the occurring descriptors. Thus, two constitutional descriptors and 
a topological one are involved in this model. The two TS molecules were within the 
descriptor space.  
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F2) To predict the activities of the remaining compounds 327 and 336 (giving rise 
to TS2) the following two-descriptor equation was derived, on the basis of TR2, 
made up of the remaining 10 molecules: 
 
pKi = 11.79 (± 1.49) + 16.39 (± 4.78) RNO – 0.122 (± 0.0281) CIC(0) 
 
R
2=0.8048; F= 14.4334; n=10; s
2=0.0732 
 
The constitutional descriptor relative number of O atom (RNO) and the topological 
complementary information content (order 0) (CIC(0)) are involved in this model. 
All the TS molecules were within the descriptor space. 
 
 
G) Isoquinoline and quinazoline derivatives 
41 Isoquinoline and quinazoline derivatives were collected from van Muijlwijk-
Koezen et al., 1998 and from van Muijlwijk-Koezen et al., 2000. Compounds 338, 
362, 363 and 371 were included in the TS. The dataset was further split in the 
following two subsets: 
 
G1) TS1 was composed of compounds 338, 363 and 371. The following one-
descriptor equation was derived, on the basis of the relevant TR1, made up of 11 
molecules: 
 
pKi = 8.54 (± 0.43) – 39.38 (± 8.75) HACA-2/SQRT(TMSA) 
 
R
2=0.6924; F=20.2622; n=11; s
2=0.0508 
 
The electrostatic descriptor involved HACA-2/SQRT(TMSA) is the total charge 
weighted HACA, where HACA is the hydrogen-acceptors charged surface area, also 
depending on the total molecular surface area. It can be understood that this 
descriptor reflects the contributions of partial charges to the total molecular 
solvent-accessible surface area. All the TS molecules were within the descriptor 
space. 
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G2) TS2 was composed of compound 362, for which the following five-descriptor 
equation was derived, on the basis of the all 37 molecules not belonging to TS1 
nor TS2: 
 
pKi = -2.04 (± 1.01) + 0.605 (± 0.142) KSI2 + 1.15 (± 0.272) RPCS + 5.66       
(± 1.97) RNCG + 0.772 (± 0.310) NR – 9.48e-03 (± 6.66e-03) CIC1 
 
R
2=0.7421; F=17.8404; n=37; s
2=0.1913 
 
The constitutional descriptor number of rings (NR), the topological descriptors Kier 
shape index (order 2) (KSI2) and complementary information content (order 1) 
(CIC1), as well as the electrostatic relative positive charged SA (RPCS), where SA 
stands for surface area, and relative negative charge (RNCG), are involved in this 
equation. A high difference between the calculated and experimental pKi values 
has to be noted for molecule 162; this may be explained by means of the poor 
chemical similarity with respect to the other compounds of the dataset. The TS 
molecule was within the descriptor space. 
 
 
H) Thiazole and thiadiazole derivatives 
54 Thiazole and thiadiazole derivatives were collected from van Muijlwijk-Koezen 
et al., 2001, and from Jung et al., 2004. Compounds 380, 384 and 395 were 
included in the TS. The dataset was further split in two subsets containing thiazole 
derivatives (H1) and thiadiazole derivatives (H2), respectively: 
 
H1) Compounds 380, 384 were included in TS1, and the following one-descriptor 
equation was derived: 
 
pKi = 14.78 (± 1.64) -2.04 (± 0.375) AIC(2) 
 
R
2=0.8321; F=29.7345; n=8; s
2=0.0618 
 
The involved descriptor is the topological average information content (order 2) 
(AIC(2)). The two TS molecules were within the descriptor space. 
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H2) To predict the activity of compound 395, belonging to TS2, the following one-
descriptor equation was derived, on the basis of the relevant TR2 made up of 6 
molecules: 
 
pKi = 14.63 (± 1.73) – 1.36 (± 0.322) KHI(2) 
 
R
2=0.8170; F=17.8559; n=6, s
2=0.1204 
 
Again, a topological index appears in the model, the Kier & Hall index (order 2) 
(KHI(2)). Molecule 395 did not fall within the descriptor space. 
 
 
I) 9-Ethylpurine derivatives 
17 9-Ethylpurine  derivatives were collected from Camaioni et al., 1998. 
Compounds 435, 437 and 446 were included in the TS. The dataset was further 
split in the following two subsets: 
 
I1) including compounds 435 and 437 in TS1, for which the following one-
descriptor equation was derived, on the basis of the relevant TR1 made up of 3 
molecules: 
 
pKi = 4.50 (± 0.0573) + 0.996 (± 0.0993) NTB 
 
R
2=0.9902; F=100.6469; n=3; s
2=0.0066 
 
This model involves the constitutional number of triple bond (NTB) as the 
descriptor. The two TS molecules were within the descriptor space. 
 
I2) including compound 446 as TS2, for which the following one-descriptor 
equation was derived, on the basis of a TR2 made up of 6 molecules: 
 
pKi = 1.11 (± 0.971) + 0.835 (± 0.223) NN 
 
R
2=0.7784; F=14.0500; n=6; s
2=0.0662 
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Again, a constitutional descriptor, the number of N atoms (NN) is involved. The TS 
molecule was within the descriptor space. 
 
L) 2-Arylpyrazolo[3,4-c]quinoline derivatives 
34 2-Arylpyrazolo[3,4-c]quinoline derivatives were collected from Colotta et al., 
2000b. Compounds 459, 469 and 481 were included in the TS. The following two-
descriptor equation was derived, on the basis of the relevant TR made up of 9 
molecules: 
 
 
pKi = 3.73 (± 0.875) + 0.233 (± 0.0711) NAB + 0.743 (± 0.275) NO 
 
R
2=0.8164; F=13.3420; n=9; s
2=0.1460 
 
Both descriptors occurring in this models are of the constitutional kind, being the 
number of aromatic bonds (NAB) and the number of O atoms (NO). All the TS 
molecules were within the descriptor space. 
 
 
M) 1-Benzyl-1H,3H-pyrido[2,1-f]purine-2,4-dione derivatives 
20 1-Benzyl-1H,3H-pyrido[2,1-f]purine-2,4-dione derivatives were collected from 
Priego et al., 2002. Compounds 484, 491 and 500 were included in the TS, split 
into TS1 and TS2. 
 
M1) TS1 was made of compound 484. Its target property value was predicted by 
the following one-descriptor equation derived on the basis of 5 molecules: 
 
pKi = -36.71 (± 20.18) + 9.96 (± 4.59) AIC(2) 
 
R
2=0.6111; F=4.7135; n=5, s
2=0.3701 
 
The model involves the topological descriptor average information content (order 
2) (AIC(2)). Molecule 485 did not fall within the descriptor space. 
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M2) TS2 comprised compounds 491 and 500, and the following two-descriptor 
equation was derived, on the basis of a TR2 made up of 10 molecules: 
 
pKi = 12.95 (± 1.53) – 0.0927 (± 0.0281) IC(0) – 0.0703 (± 0.0337) CIC(2) 
 
R
2=0.6928; F=7.8926; n=10; s
2=0.3243 
 
Topological descriptors appears in this model too: they are the information 
content (order 0) (IC(0)) and the complementary information content (order 2) 
(CIC(2)). The two TS molecules were within the descriptor space. 
 
 
N) Xanthine and 9-deazaxanthine derivatives 
18 Xanthine and 9-deazaxanthine derivatives were collected from Hayallah et al., 
2002 and from Linden et al., 1999. Compounds 506, 512 and 521 were included 
in the TS. The following two-descriptor equation was derived, on the basis of the 
relevant TR comprising all the remaining molecules: 
 
pKi = 2.47 (± 0.881) + 173.27 (± 50.24) MPCC – 43.46 (± 11.02) MPCN 
 
R
2=0.6003; F=9.0102; n=15, s
2=0.1051 
 
The electrostatic descriptors involved, the Minimum partial charge for a C atom 
(MPCC) and the minimum partial charge for a N atom (MPCN) indicated the 
importance of the charge distribution for this kind of molecules to interact with the 
adenosine A3 receptor. All the TS molecules were within the descriptor space. 
 
 
O) Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives 
11 Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives were collected from 
Baraldi et al., 2003. Compounds 522 and 524 were included in the TS. The 
following two-descriptor equation was derived, on the basis of the relevant TR 
comprising all the remaining molecules: 
 
pKi = -10.75 (± 5.77) + 18.20 (± 6.36) ABIC(1) + 2.11 (± 0.934) HACA-2  
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R
2=0.6567; F=5.7397; n=9, s
2=0.1668 
 
Are involved in this equation the topological descriptor average bonding 
information content (order 1) (ABIC(1)) and the already mentioned electrostatic 
descriptor HACA-2. Molecule 525 did not fall within the descriptor space. 
 
 
P) Pyrrolo[2,3-d]pyrimidine-4-amine derivatives 
7 Pyrrolo[2,3-d]pyrimidine-4-amine derivatives collected from Hess et al., 2000. 
Compounds 535, 538 and 539 were included in the TS. The remaining compounds 
were used to derive the following one-descriptor equation: 
 
pKi = 20.46 (± 1.86) + 152.26 (± 19.37) MPCN 
 
R
2=0.9686; F=61.7858; n=4, s
2=0.0619 
 
This model involves the electrostatic descriptor minimum partial charge for a N 
atom (MPCN). All the TS molecules were within the descriptor space. 
 
 
2.2. Model from the whole database (“full” model) vs the combination of 
“local” models (“combined” model) 
Predicted values of the target property were simultaneously carried out by 
combining the use of the “local” models previously obtained, in order to estimate 
if and how much that could globally improve the predictive power. Fig. 1 
illustrates the plot of the pKi,  calculated by using all the single “local” models, 
versus the experimental pKi values. 
 
Statistic parameters for the overall TS are the following: 
 
R
2 = 0.7125, k = 0.8207, k0 = 0.9957, (R
2-R0
2)/R
2 = 0.04702 
 
where R
2 is the correlation coefficient of the regression line, k is its slope, k0 is the 
slope of the regression line forced through the origin of the axes and R0
2 is the  
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correlation coefficient of this latter line. For a comparison of the above results with 
the ones from Moro et al. the R value reported in their paper is shown below: the 
Moro’s value is R = 0.82 (R
2 = 0.67) on the same TS, with a slope of 0.57. 
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Fig. 1 Calculated versus experimental pKi values. The full line is the regression 
line for the TS calculated by using all the single “local” models, while the dotted 
line is the regression line forced to pass through the origin of the axes. 
 
 
Since the “combined” model, coming from the assembly of the local models, 
works better than the model built on the whole database (“full” model) it can be 
suggested that the affinity values experimentally found for a given receptor may 
not to be well represented by a single continuous multi-linear function; it may be 
better represented by a discontinuous function obtained by the combination of 
different functions as shown in Fig. 2. As it often happens when dealing with 
biological systems, although it is not possible to find a correlation along the entire 
function, it is possible to find ranges within which the function itself may be 
approximated by multi-linear regression. 
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Fig. 2. In analogy to a discontinuous mathematical function, QSAR models may 
be built by splitting the whole dataset into smaller groups of compounds. a…n 
are the coefficients, d1…dn are the variables (descriptors), and D
1…D
m are the 
applicability domains of the QSAR models, being the latter defined by both the 
descriptor space and the molecular similarity. 
 
 
2.3. “Inter-class” experiments aimed at “Lead finding” 
A significant step in the strategies aimed at obtaining new drugs is represented by 
the identification of a “lead compound” endowed of a well defined activity towards 
a biological target. The design of a new chemical class, containing a candidate 
lead, starts by analyzing already know classes of compounds, which may range 
from natural compounds to synthetic molecules. Thus, a medicinal chemist should 
capture information from given classes of existing compounds and use it for 
designing New Chemical Entities (NCEs). Here an attempt of integrating the 
information, coming from structurally different classes of compounds which acts at 
the same biological target, is made, in order to estimate the possibility of 
expanding the predictive potential of models based on focused databases. 
A first experiment carried out in order to exemplify this concept implied the use of 
the QSAR equation derived from dataset E (1,2,4-triazolo[4,3-a]quinoxalin-1-one 
derivatives collected from Moro et al., 2005b) to predict activity values of 
compounds belonging to dataset O (pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidine derivatives collected from Baraldi et al., 2003). Three further 
experiments were performed (“inter-class” experiments). All the examined cases 
showed that reliable prediction of the property of interest may be obtained, within 
a chemical class, by using the model developed for a different class of 
compounds, acting at the same receptor, with minor loss of accuracy. The 
accuracy of the predictions is comparable to the experimental error which is 
commonly recognized to affect the biological data in a database. On this regard it 
i s  u s e f u l  t o  r e c a l l  w h a t   h a s  b e e n  p r e v iously reported about differences in pKi 
values of the same molecule, depending on experimental conditions. For the same 
compound the activity data available differ from each other by up to one  
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logarithmic unit, when tested with different protocols and/or by different research 
groups. In accordance with this observation, and considering that different classes 
of molecules, previously measured by different research groups, do supply the 
biological data to be exploited in developing QSAR models, it is straightforward to 
consider as acceptable an error of about 1, calculated for predicted pKi on the TS. 
In spite many authors are engaged in decreasing the error in their predictions, the 
point to consider here is how relevant is, in predicting pKis within a given virtual 
library, the effort aimed at obtaining errors which are below the experimental 
errors themselves. 
In this section the results of “inter-class” predictive experiments, are described. 
The differences between experimental and calculated pKi values for each TS, and 
the descriptor space for each experiment are reported. 
 
a) TR: dataset E (104 triazolo[4,3-a]quinoxalin-1-one derivatives collected from 
Moro et al., 2005b). TS: dataset O (11 pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidine derivatives collected from Baraldi et al., 2003). The following five-
descriptor equation was derived: 
 
pKi = 17.86 (± 1.26) + 51.61 (± 4.81) MPCO + 5.61 (± 1.17) RNAB + 24.34 (± 
7.09) RNBr + 12.90 (± 4.32) MPCC – 7.44e-04 (± 1.11e-04) GIAB 
 
R
2=0.6582; F= 37.7465; n=104 
 
 
In this model two electrostatic descriptors, i.e. the maximum partial charge for a 
O atom (MPCO) and the maximum partial charge for a C atom (MPCC), two 
constitutional descriptors, the relative number of aromatic bonds (RNAB) and the 
relative number of Br atoms (RNBr), and a geometrical descriptor, the gravitation 
index (all bonds) (GIAB) are involved. Table 1 and Table 2 show the prediction 
errors obtained for the TS, and the descriptor space, respectively. All the TS 
molecules were within the descriptor space. 
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Table 1. Comparison between experimental and calculated pKi values at the adenosine A3 
receptor. 
 
Calculated pKi Experimental  pKi Difference Compound 
6.3102 6.6478  -0.3376  522 
a 
8.5318 8.0458  0.4861  531 
6.6494 6.4584  0.191  532 
5.9902 7.4559  -1.4657  523 
5.6732 6.6498  -0.9766  524
 a 
8.5334 7.8539  0.6795  525 
8.2432 6.6737  1.5695  526 
7.3073 6.9586  0.3487  527 
7.5998 6.7375  0.8622  528 
8.4197 6.5114  1.9083  529 
* 
6.3105 7.6021  -1.2915  530 
 
* Compound 530 shows only a poor chemical similarity with the other 
molecules of the dataset. 
a Compounds belonging to Moro’s TS. 
 
 
Table 2. Minimum and maximum values of descriptors involved in the correlation equation for 
the adenosine A3 receptor 
 
Descriptor MPCO  GIAB RNAB  RNBr  MPCC 
Min  -1.554 5.12e+3  0  0  0.0732 
Max  -0.0617 1.42e+4 0.3696 0.1034 0.1776 
 
All the TS molecules were within the descriptor space. 
 
 
b) TR: dataset I (7 9-ethylpurine  derivatives collected from Camaioni et al., 
1998). TS: dataset P (13 pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine 
derivatives collected from Baraldi et al., 2003). The following two-descriptor 
equation was derived: 
 
pKi = -0.673 (± 1.09) + 0.65 (± 0.11) NN + 0.20 (± 0.07) NSB 
 
R
2=0.7927; F=19.1213; n=13 
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Both descriptors belong to the constitutional group: the number of N atoms (NN) 
and the number of singe bonds (NSB). Table 3 and Table 4 show the prediction 
errors obtained for the TS, and the descriptor space, respectively. All the TS 
molecules fell outside the descriptor space. 
 
 
Table 3. Comparison between experimental and calculated pKi values at the adenosine A3 
receptor. 
 
Calculated pKi Experimental  pKi Difference Compound 
3.9002 7.5528  -3.6526  533
* 
5.7605 5.5784  0.1821  534 
4.5049 4.9431  -0.4382  535 
a 
5.1095 5.063  0.0466  536 
5.1559 5.2534  -0.0975  537 
5.1095 6.2441  -1.1346  538
 a 
5.5126 5.7282  -0.2155  539
 a 
 
* Compound 533 shows only a poor chemical similarity with the other 
molecules of the dataset. 
a. Compounds belonging to Moro’s TS. 
 
 
Table 4. Minimum and maximum values of descriptors involved in the correlation equation for 
the adenosine A3 receptor 
 
Descriptor NN  NSB 
Min  4 10 
Max  6 14 
 
All the TS molecules fell outside the descriptor space. 
 
 
c) TR: datasets D, E, F, G and I (202 molecules: imidazo[2,1-i]purin-5-one 
derivatives collected from Müller e t  a l . ,  2 0 0 2 ;  t r i a z o l o [ 4 , 3 - a]quinoxalin-1-one 
derivatives collected from Moro et al., 2005b; 1,2,4-triazolo[4,3-a]quinoxalin-1-
one derivatives collected from Colotta et al., 2000a; isoquinoline and quinazoline 
derivatives collected from van Muijlwijk-Koezen et al., 1998 and from van 
Muijlwijk-Koezen et al., 2000; and 9-ethylpurine  derivatives collected from 
Camaioni et al., 1998). TS: dataset M (20 1-benzyl-1H,3H-pyrido[2,1-f]purine- 
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2,4-dione derivatives collected from Priego et al., 2002). The following four-
descriptor equation was derived: 
 
pKi = 3.42 (± 0.374) + 0.453 (± 0.0552) NN + 0.235 (± 0.106) NBR + 0.528 (± 
0.0926) NO – 14.83 (± 4.82) RNBr 
 
R
2=0.6319; F= 84.5591; n=202 
 
All the descriptors involved in the model belong to the constitutional group: 
number of N atoms (NN), number of benzene rings (NBR), number of O atoms 
(NO) and relative number of Br atoms (RNBr). Tables 5 and 6 show the prediction 
errors obtained for the TS, and the descriptor space, respectively. All the TS 
molecules were within the descriptor space. 
 
 
 
Table 5. Comparison between experimental and calculated pKi values at the adenosine A3 
receptor. 
 
 
 
Calculated pKi Experimental  pKi Difference Compound 
6.6527 6.4318  0.2209  484
 a 
6.6527 8.3768  -1.724  493 
6.6527 8.2007  -1.5479  494 
6.6527 6.9431  -0.2904  495 
6.6527 8.301  -1.6483  496 
6.6527 7.8539  -1.2011  497 
7.8179 5.9488  1.869  498 
6.9066 7.1135  -0.2069  499 
7.4892 6.6716  0.8175  500
 a 
6.3989 5.52  0.8789  501 
7.2353 8.0809  -0.8456  502 
7.2353 6.6778  0.5575  485 
6.6527 7.1675  -0.5148  503 
6.6527 6.2557  0.397  486 
6.9066 6.699  0.2076  487 
6.6527 8.3979  -1.7452  488 
7.2353 8  -0.7647  489 
6.6527 6.0223  0.6305  490  
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6.9066 7.4559  -0.5494  491
 a 
6.6527 7.4437  -0.791  492 
 
All these compounds show only a poor chemical similarity with the molecules belonging to TR. 
 a. Compound belonging to Moro’s TS. 
 
 
Table 6. Minimum and maximum values of descriptors involved in the correlation equation for 
the adenosine A3 receptor 
 
Descriptor NN  NBR  NO  RNBr 
Min  2 0 0  0 
Max  9 4 5  0.1034 
 
All the TS molecules were within the descriptor space. 
 
 
d) TR: datasets E, F, G, I and L (230 molecules: triazolo[4,3-a]quinoxalin-1-one 
derivatives collected from Moro et al., 2005b; 1,2,4-triazolo[4,3-a]quinoxalin-1-
one derivatives collected from Colotta et al., 2000a; isoquinoline and quinazoline 
derivatives collected from van Muijlwijk-Koezen et al., 1998 and from van 
Muijlwijk-Koezen et al., 2000; 9-ethylpurine derivatives collected from Camaioni 
et al., 1998; and 2-arylpyrazolo[3,4-c]quinoline derivatives collected from Colotta 
et al., 2000b). TS: dataset N (18 xanthine and 9-deazaxanthine  derivatives 
collected from Hayallah et al., 2002 and from Linden et al., 1999). The following 
five-descriptor equation was derived: 
 
pKi = 0.756 (± 0.703) + 0.510 (± 0.0846) NO + 18.16 (± 2.70) RNR + 0.0587 
(±0.0121) NB + 0.206 (±0.0432) NN – 14.21 (± 4.70) RNBr 
 
R
2=0.6143; F= 71.3624; n=230 
 
Again, all the descriptors involved are of the constitutional type, being the number 
of O atoms (NO), the relative number of rings (RNR), the number of bonds (NB), 
the number of N atoms (NN), and the relative number of Br atoms (RNBr). Tables 
7 and 8 show the prediction errors obtained for the TS, and the descriptor space, 
respectively. All the TS molecules were within the descriptor space. 
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Table 7. Comparison between experimental and calculated pKi values at the adenosine A3 
receptor. 
 
Calculated pKi Experimental  pKi Difference Compound 
6.4843 6.0996  0.3847  504 
7.8682 5.9237  1.9445  513 
7.8682 7.0937  0.7745  514 
6.4843 5.6782  0.8061  515 
6.4085 6.4202  -0.0117  516
 a 
8.0419 6.3747  1.6672  517 
9.1515 6.1701  2.9814  518 
8.8864 6.3233  2.5631  519 
8.8839 6.9914  1.8925  520 
8.438 7.8239  0.6141  521
 a 
6.699 6.0223  0.6767  505 
5.8669 6.762  -0.8951  506
 a 
5.8669 6.3215  -0.4546  507 
7.4153 5.3352  2.0802  508 
7.3833 5.5441  1.8392  509 
8.0706 5.9266  2.1439  510 
7.3833 5.9147  1.4686  511 
7.3583 5.9512  1.4071  512 
 
All these compounds show only a poor chemical similarity with the molecules 
belonging to TR. 
a. Compounds belonging to Moro’s TS. 
 
 
Table 8. Minimum and maximum values of descriptors involved in the correlation equation for 
the adenosine A3 receptor 
 
Descriptor NO RNR NB  NN RNBr 
Min  0 0.0652  14  2  0 
Max  4 0.2222  49  9 0.1034 
 
All the TS molecules were within the descriptor space. 
 
 
  
 
77
3. Conclusion 
The great variety of experiments carried out in this work allowed drawing several 
considerations about the development of QSAR models. 
In the literature, the most usual trend in QSAR model development consists of 
selecting a dataset of compounds, splitting it into training set (TR) / test set (TS) 
couples, developing the QSAR model on the basis of the TR itself, using that 
model to carry out predictions on the TS and validating the model by means 
statistical parameters. Despite this tendency, here a novel “dynamic” protocol is 
presented, for selecting molecules to be included in the TR on the basis of the 
molecules belonging to TS. Such a protocol allowed performing experiments which 
showed that small and targeted TRs can work better than the large ones and may 
results in models endowed of higher predictive ability. 
 
Moreover, most of the naturally occurring phenomena can not be mathematically 
represented by a continuous function in their entirety; nevertheless it is often 
possible to individuate inner ranges of variables within which satisfying 
approximation may be obtained by a given mathematical function. This principle 
turns out to be well suited QSAR studies. It may be applied, by splitting a large 
database into smaller datasets, in order to find “local” models, whose combination 
can exhibit a very good prediction ability with respect to a previously defined TS. 
 
Furthermore, the selection of a suitable targeted training set, which the test set to 
be used in the validation step is representative for, implies some advantages. In 
fact, the use of a TR containing information that is not relevant for the problem at 
hand may lead to miscorrelation, while a too large TR, carrying redundant 
information, may give rise to over-fitting problems. A focused selection of the TR, 
modeled on the basis of a previously selected TS, should ensure that each 
molecule belonging to the TS has at least one representative molecule in the TR 
as well as to obey to the “principle of parsimony”, which “calls for using models 
and procedures that contain all that is necessary for the modeling but nothing 
more”. (Hawkins, 2004). 
 
As a final consideration it is worth to mention that any QSAR model can be 
unfailingly applied only inside its particular validity domain, which is related to the 
descriptor space of the model itself. To test the goodness of the prediction ability 
of a QSAR model, both “intra-class” and “inter-class” predictions were carried out.  
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In the first case, each TS and its selected TR comprised compounds of the same 
chemical class, identified according to a qualitative estimate of their chemical 
similarity. In the second case models were developed on the basis of TRs selected 
for a given TS and such models were used to predict both the related TS, and a 
different TS referring to molecules of a different chemical class (obviously acting 
on the same biological target). In each type of experiment that was performed, 
the importance that a given molecule in the TS falls into the so-called “descriptor 
space” was highlighted. The strictest requirement was referred to the chemical 
similarity of the TS molecules with regard to the ones exploited for developing the 
model (relevant TR), also in agreement with Sheridan et al., 2004. This 
characteristic emerged both during the development of the “local” models (for 
example compound 162) and during the “inter-class” experiments (for example 
dataset N, comprising xanthine and 9-deazaxanthine derivatives). 
 
“Inter-class” experiments and “local” models point out the important role of QSAR 
in “lead finding” and “lead optimization”, respectively. As a final conclusion it may 
be highlighted that the novelty of the work presented here relies in the 
development of a protocol strictly reproducing the processes carried forward by a 
medicinal chemist’s mind. 
 
 
4. Experimental section 
Dataset Preparation 
The whole dataset containing 539 molecules was built by using structural and 
biological data collected from the literature. See each single model for respective 
references and supporting information for structural and affinity data. The 2D-
structures were used to calculate the constitutional and topological descriptors, as 
well as those electrostatic descriptors not requiring the knowledge of 3D 
geometry. For the models showing poor correlation, 3D-structures were built, in 
order to allow calculation of three-dimensional (geometrical and all the 
electrostatic) descriptors. In the latter case, all the initial geometries were built by 
using the InsightII molecular modeling program (Accelrys Inc., San Diego, CA). 
The molecules were solvated with a layer of 5 Å, and the pH was set to the 
physiological value of 7.4. The structures initially selected for accurate geometry  
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optimization were energy minimized. All the energy minimizations were carried 
out with a Molecular Mechanics (MM) approach implemented in the Discover 
program (Accelrys Inc., San Diego, CA), by using 1000 steps of steepest descent, 
followed by conjugated gradient until potential energy rms < 0.05 Kcal/mol. The 
cff91 force-field was selected and a distance-dependent dielectric function (ε=1r) 
was used. All the calculations were run on Silicon Graphics (SGI) R10000 197 
MHz. 
 
Protocol for QSAR equation development 
In developing the models, the ratio between the TS and TR molecules (usually 
about 15-20:100) was mostly kept higher than 20%. Moreover, the ratio between 
the number of descriptors (independent variables) and the one of molecules 
belonging to the TR (usually lower than 1:5), was mostly taken lower than such a 
threshold. The upper limit on the number of descriptors allows avoiding over-
fitting problems. In few cases unusual ratios were taken, after several attempts, 
just in order to explore the chemical space of validity for the models. In building 
all the QSAR models and selecting the best ones, the dynamic procedure 
mentioned below was followed. 
1.  Selection of proper molecules to be used in defining the TS. 
2.  All the molecules of the TS (single compounds or groups of compounds) 
were classified on the basis of a commonly shared template easily 
recognized by inspecting the molecular structures. 
3.  The same classification was applied to the molecules of the TR. 
4.  A suitable class of molecules for TR was associated to each class of 
molecules of the selected TS, where superimposition of molecular 
structures appeared to be feasible. When a class of compounds in the TS 
did no share a main common template with any class of the TR, the 
classes of the TR where superimposition of molecular structures appeared 
to be most feasible were chosen to represent it. 
5.  Within each class of the TS, we took into account how many substituents 
and which positions they were taking, with respect to the main template. 
This step was repeated for the TR classes. 
6.  The correspondence of the substitution patterns between the TS and the 
related TR molecules was analyzed within each class or across different 
chemical classes.  
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7.  For each particular class, the TR molecules possessing variable 
substituents endowed with the higher similarity with the substituents of 
related TS molecules were selected. This was achieved also attempting to 
retain at least five representative compounds for each variable position, 
and about the same number of compounds (ratio ≈ 1 )  t h a t  w a s  
representative of each position, according to the total number of 
compounds. This is because 5 is the suitable number of elements to build 
an appropriate correlation (Swinscow, 1997) and because the optimal 
ratio between number of observations (molecules) and number of 
variables (descriptors) is 5:1 (Cronin and Schultz, 2003). The selected 
molecules gave rise, for each class, to a new reduced TR (TRi). 
8.  All the structures, as well as their pKi values, belonging to the TRis were 
processed by the CODESSA software
  (http://www.codessa-pro.com), 
which automatically calculated constitutional, topological and, when 
required, geometrical and electrostatic descriptors for each molecule. 
Then, a number of correlation equations was generated by the program, 
on the basis of an automatic heuristic selection of the calculated 
descriptors. At this level, the control parameters were set a little lower 
with respect to the ones taken by default within the program, in order to 
limit the inter-correlation between descriptors. In particular, rfull = 0.90 
(instead of 0.99) and rsig = 0.70 (instead of 0.80) were chosen. 
9.  The best correlation equations were selected on the basis of the R
2 
(correlation coefficient) value for each TRi. The threshold was set at R
2 = 
0.6. 
10.  The validity domain of each model, defined by the above mentioned   
descriptor space (previously described in ref 5), was analyzed for each 
TRi. 
11.  Likewise the TRis, all the molecules of all the TSs were loaded into 
Codessa and submitted to the calculation of descriptors. The value of 
each descriptor occurring in the model was calculated for each molecule 
of each TS. This allowed finding out if each molecule fell or not into the 
descriptor space ranges, i.e. if that molecule was predicted by 
interpolation or extrapolation.  
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12.  Finally, the prediction errors, that are the differences between calculated 
and experimental pKi values, were calculated. 
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Appendix A 
 
Table 1. Structures and affinity  values at the human adenosine A3 receptor of 
flavonoid derivatives 
 
O
O
R1
R2
R3
O
O
R1
R2
R3
(trans) O
O
R2
R1
O
O
O
R3
R1
R2
1-16 17-22 23-29 30-36
 
 
Comp. R1  R2  R3  Ki (nM ± SEM) 
1  OH Ph  5,7-(OH)2  3.15 ± 0.85 
2  OMe Ph  5,7-(OMe)2  1.21 ± 0.30 
3  OEt Ph  5,7-(OEt)2  0.364 ± 0.067 
4  OEt  Ph  5-OH-7-OEt  0.748 ± 0.402 
5  OPr Ph  5,7-(OPr)2  0.317 ± 0.089 
6  CH2CH=C(CH3)2 2’,4’-(OH)2Ph 
5-OH-6-CH=CHCH- 
(CH3)27-OMe 
4.59 ± 1.69 
7  OMe 2’,4’-(OMe)2Ph 5,7-(OMe)2  2.65 ± 0.72 
8  OEt 2’,4’-(OEt)2Ph  5-OH-7-OEt  4.83 ± 1.40 
9  OEt 2’,4’-(OEt)2Ph 5,7-(OEt)2  7.27 ± 1.88 
10  OH 2’,4’,6’-(OMe)3Ph  H  50.1 ± 7.8 
11  OH  C￿CPh  6-OMe  24.0 ± 9.7 
12  H  Ph  H  16.9 ± 3.8 
13  Cl  Ph  H  11.5 ± 3.7 
14  Cl  Ph  6-Cl  0.741 ± 0.325 
15  Cl  2’-iPrO-4’-MePh  6-Cl  0.561 ± 0.129 
16  Cl 2’,4’,6’-Me3Ph  6-Cl  5.24 ± 0.52 
17  H  Ph  H  50.1 ± 27.1 
18  H  2’-OHPh  H  6.07 ± 1.43 
19  H  4’-OHPh  H  42.8 ± 10.5 
20  H  4’-OHPh  5-OH-7-OMe  3.40 ± 0.18 
21  OH  CH=CHPh  6-OMe  21.1 ± 9.9 
22  OH  C￿CPh  6-OMe  8.17 ± 0.43 
23  OMe  Me    60.0 ± 17.8 
24  OMe  CHO    88.9 ± 27.1 
25  OMe  CH=CHPh    8.28 ± 2.69 
26  OEt  CH=CHPh    1.16 ± 0.45 
27  O(CH2)2CH3  CH=CHPh    3.95 ± 1.98 
28  OEt  CH=CHCH=CHPh    45.5 ± 10.3  
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29  OMe  CH=NPh    9.18 ± 2.56 
30  5-OH-7-Me  4’-OMe  H  6.70 ± 1.78 
31  5,6,7-(Me)3  4’-Me  H  4.48 ± 0.14 
32  5-OH-6,7(MeO)2  4’-OH  H  1.72 ± 0.19 
33  5,7-(AcO)2  H  OAc  17.5 ± 2.0 
34  5,7-(MeO)2  4’-OMe  OMe  3.37 ± 1.83 
35  7-OMe 3’,4’-(OH)2  OH  1.38 ± 0.18 
36  5,7-(MeO)2 3’,4’,5’-(OMe)3  OMe  16.2 ± 2.2  
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Table 2. Structures and affinity values at the human adenosine A3 receptor of pyridine and dihydropyridine derivatives 
 
N
H
R2
R3
R4
R5
R6
37-59, 147
N
H
C H3
R4
R6
O
O O
O
R3 R5
60-80
N C H3
R4 O
O O
O
R5
81-82
N
H
R2
R4
R6
O
R3 O
O
H
R5
83-97
N R2
R4
R6
O
R3 O
O
R5
98-123
N R2
R4
R6
O
S O
O
124-146
R5 R3
 
Comp. R2  R3  R4  R5  R6 Ki (μM ± SEM) 
37  CH3 CO2CH3 CH3 CO2(CH2)2OCH3 CH3  62.3 ± 16.7 
38  CH3 CO2CH3 CH3 CO2CH2Ph CH3 2.78±  0.89 
39  CH3 CO2CH2CH3 CH3 CO2(CH2)2SPh CH3  5.56 ± 1.36 
40  CH3 CO2CH3 CH2CH3 CO2CH2CH3 CH3  13.6 ± 2.0 
41  CH3 CO2CH3 (CH2)2CH3 CO2CH2CH3 CH3  6.51 ± 0.74 
42  CH3 CO2CH3 CH2CHCH3(CH2)2- 
CH=C(CH3)2 (R,S) 
CO2CH2CH3 CH3  7.90 ± 0.88 
43  CH3 CO2CH3 Ph  CO2CH2CH3 CH3  12.0 ± 3.3  
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44  CH3 CO2CH3 2-NO2Ph CO2CH3 CH3  8.29 ± 2.41 
45  CH3 CO2CH3 3-NO2Ph CO2CH2CH3 CH3  8.30 ± 1.41 
46  CH3 CO2CH2CH3 3-NO2Ph CO2CH2CH3 CH3  2.51 ± 0.15 
47  CH3 CO2CH3 3-NO2Ph CO2CH2CH2N(CH3)CH2Ph CH3  3.25 ± 0.26 
48  CH3 CO2CH(CH3)2 3-NO2Ph CO2CH2CH2OCH3 CH3  8.47 ± 2.75 
49  CH3 CO2CH3 3-NO2Ph  CO2(CH2)3N
Ph
Ph
 
CH3  2.80 ± 0.35 
50  CH3 CO2CH3 4-NO2Ph CO2CH2CH3 CH3  5.90 ± 1.65 
51  CH3 CO2CH3 2-CF3Ph CO2CH2CH3 CH3  11.6 ± 1.7 
52  CH3 CO2CH3 4-CH3OPh CO2CH2CH3 CH3  4.10 ± 0.14 
53  CH3 CO2CH3 3-CH3O-4-OHPh CO2CH2CH3 CH3  32.1 ± 9.2 
54  CH3 CO2CH3 3,4-OCH2OPh CO2CH2CH3 CH3  4.58 ± 1.1 
55  CH3 CO2CH3 Ph  CH2CH3 CO2CH2CH3 CH3  2.30 ± 0.70 
56  CH3 CO2CH3 Ph-CH=CH-(trans) CO2CH2CH3 CH3  0.670 ± 0.195 
57  CH3 CO2CH3 Ph-C￿C-  CO2CH2CH3 CH3  0.940 ± 0.070 
58  CH3 CO2CH2CH3 CH3 CO2CH2CH3 (CH2)3CH3  47.1 ± 10.8 
59  CH3 CO2CH2CH3 Ph-CH=CH-(trans) CO2CH2CH3 CH3  0.108 ± 0.012 
60   CH2CH3 Ph-CH=CH-(trans) CH2CH3 CH3  0.887 ± 0.138 
61   CH2CH3 Ph-CH=CH-(trans) CH2Ph CH3  3.13 ± 0.51 
62   CH2CH3 CH2CH3 CH2CH3  Ph  8.49 ± 1.74 
63   CH2CH3 CH3 CH2Ph  Ph  1.75 ± 0.47 
64   CH2CH3 Ph-CH=CH-(trans) CH2CH3 4-CH3Ph  9.13 ± 2.43 
65   CH2CH3 Ph-CH=CH-(trans) CH2CH3 4-OCH3Ph  1.43 ± 0.37 
66   CH2CH3 Ph-CH=CH-(trans) CH2CH3  4-ClPh  0.785 ± 0.272 
67   CH2CH3 Ph-CH=CH-(trans) CH2CH3 4NO2Ph  4.14 ± 0.51 
68   CH2CH3 Ph-CH=CH-(trans) CH2CH3  3-furyl  0.907 ± 0.307 
69   CH2CH3 Ph-CH=CH-(trans) CH2CH3  3-thienyl  0.407 ± 0.066 
70   CH2CH3 2-OCH3Ph-CH=CH-(trans) CH2CH3  Ph  0.334 ± 0.059 
71   CH2CH3 2-NO2Ph-CH=CH-(trans) CH2CH3  Ph  0.109 ± 0.017  
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72   CH2CH3 4-NO2Ph-CH=CH-(trans) CH2CH3  Ph  0.0585 ± 0.0164 
73   CH2CH3 4-NH2Ph-CH=CH-(trans) CH2CH3  Ph  0.198 ± 0.047 
74   CH2CH3 (Ph)2CH=CH- CH2CH3  Ph  1.42 ± 0.23 
75   CH2CH3 Ph-C￿C-  CH2CH3  Ph  0.0766 ± 0.0151 
76   CH2CH3 Ph-CH=CH-(trans) CH2Ph  Ph  0.0583 ± 0.0124 
77   CH2CH3   CH2Ph  Ph  0.0724 ± 0.0377 
78   CH2Ph Ph-CH=CH-(trans) CH2CH3  Ph  0.142 ± 0.047 
79   CH2Ph 4-NO2Ph-CH=CH-(trans) CH2CH3  Ph  0.286 ± 0.038 
80   CH2Ph Ph-C￿C-  CH2CH3  Ph  0.169 ± 0.026 
81     Ph-CH=CH-(trans) CH2CH3    2.80 ± 1.78 
82     Ph-C￿C- CH2Ph    2.75 ± 0.78 
83  CH3 OCH2CH2CH3 CH3 CH2CH3  Ph  2.11 ± 0.35 
84  CH3 OCH2CH3 CH2CH3 CH2CH3  Ph  2.27 ± 0.64 
85  CH3 SCH2CH3 CH2CH3 CH2CH3  Ph  2.01 ± 0.55 
86  CH3 SCH2CH2OCH3 CH2CH3 CH2CH3  Ph  4.58 ± 0.35 
87  CH3 SCH2CH3 CH2CH2CH3 CH2CH3  Ph  2.17 ± 0.25 
88  CH3 SCH2CH3 CH2CH3 CH2Ph  Ph  1.65 ± 0.40 
89  CH3 OCH2CH3 CH(OCH3)2 CH2CH3  Ph  15.3 ± 3.9 
90  CH3 OCH2CH3 CHO  CH2CH3  Ph  15.6 ± 5.4 
91  CH3 OCH2CH3 Ph-C￿C-  CH2Ph  cyclopropyl  0.0277 ± 0.0024 
92  CH3 OCH2CH3 Ph-C￿C-  CH2Ph  cyclobutyl  0.0225 ± 0.0030 
93  CH3 OCH2CH3 Ph-C￿C-  CH2Ph  cyclopentyl  0.0505 ± 0.0210 
94  CH3 OCH2CH3 Ph-C￿C-  CH2Ph  cyclohexyl  0.229 ± 0.014 
95  CH2CH3 OCH2CH3 CH3 CH2CH3  Ph  2.83 ± 0.20 
96  CH2CH3 SCH2CH3 CH2CH3 CH2CH3  Ph  0.907 ± 0.044 
97  CH2CH2CH3 SCH2CH3 CH2CH3 CH2CH3  Ph  2.09 ± 0.04 
98  CH3 OCH2CH2CH3 CH3 CH2CH3  Ph  0.215 ± 0.022 
99  CH3 OCH2CH3 CH2CH3 CH2CH3  Ph  0.176 ± 0.38 
100  CH3 SCH2CH3 CH2CH3 CH2CH3  Ph  0.0429 ± 0.0088  
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101  CH3 SCH2CH2OCH3 CH2CH3 CH2CH3  Ph  0.165 ± 0.012 
102  CH3 SCH2CH3 CH2CH2CH3 CH2CH3  Ph  0.194 ± 0.051 
103  CH3 SCH2CH3 CH2CH3 CH2Ph  Ph  2.61 ± 0.96 
104  CH3 OCH2CH3 CH(OCH3)2 CH2CH3  Ph  0.783 ± 0.154 
105  CH3 OCH2CH3 CHO  CH2CH3  Ph  1.98 ± 0.21 
106  CH3 OCH2CH3 Ph-CH=CH-(trans) CH2CH3  Ph  2.80 ± 1.78 
107  CH3 OCH2CH3 Ph-C￿C-  CH2Ph  Ph  2.75 ± 0.78 
108  CH3 OCH2CH3 Ph-C￿C-  CH2Ph  cyclobutyl  2.41 ± 0.59 
109  CH3 OCH2CH3 Ph-C￿C-  CH2Ph  cyclopentyl  3.85 ± 0.79 
110  CH2CH3 OCH2CH3 CH3 CH2CH3  Ph  0.121 ± 0.008 
111  CH2CH3 OH  CH2CH3 CH2CH3  Ph  1.28 ± 0.55 
112  CH2CH3 SCH2CH3 CH2CH3 CH2CH3  Ph  0.0200 ± 0.0019 
113  CH2CH3 SCH2CH3 CH2CH3 CH2CH2CH3  Ph  0.00829 ± 0.00115 
114  CH2CH3 SCH2CH3 CH2CH2CH3 CH2CH2CH3  Ph  0.0189 ± 0.0041 
115  CH2CH3 SCH2CH3 CH2CH3 CH2CH2OH  Ph  0.155 ± 0.061 
116  CH2CH3 SCH2CH3 CH2CH3 CH2CH3  3-Cl-Ph  0.0134 ± 0.0015 
117  CH2CH3 SCH2CH3 CH2CH3 CH2CH3  cyclopentyl  3.38 ± 1.87 
118  CH2CH3 SCH2CH2CH3 CH2CH3 CH2CH3  Ph  0.0159 ± 0.0054 
119  CH2CH3 SCH2CH2CH3 CH2CH3 CH2CH2CH3  3-Cl-Ph  0.00794 ± 0.00319 
120  CH2CH2CH3 SCH2CH3 CH2CH3 CH2CH3  Ph  0.0333 ± 0.0107 
121  (CH2)2OCH3 SCH2CH3 CH2CH3 CH2CH3  Ph  0.0168 ± 0.0020 
122  (CH2)3CH3 SCH2CH3 CH2CH3 CH2CH3  Ph  0.0350 ± 0.091 
123  cyclobutyl SCH2CH3 CH2CH3 CH2CH3  Ph  0.145 ± 0.044 
            
 
 
 
  
 
90
Comp. R2  R3  R4  R5  R6 Ki (nM ± SEM) 
124  CH2CH3 CH2CH3 CH2CH2CH3 CH2CH2CH3  Ph  18.9 ± 4.1 
125  CH2CH3 CH2CH3 CH2CH3 CH2CH3  Ph  20.0 ± 1.9 
126  CH2CH3 CH2CH3 CH2CH3 CH2CH2F  Ph  4.22 ± 0.66 
127  CH2CH3 CH2CH3 CH2CH2N-Pth CH2CH3  Ph  243 ± 43 
128  CH2CH3 CH2CH3 CH2CH3 CH2CH2CH3  Ph  8.29 ± 1.15 
129  CH2CH2OH (CH2)5CH3 CH2CH3 CH2CH2CH3  3-Cl-Ph  220 ± 57 
130  CH2CH2OCH2Ph CH2CH3 CH2CH2CH3 CH2CH2CH3  Ph  109 ± 1 
131  CH2CH2SCOCH3 CH2CH3 CH2CH2CH3 CH2CH3  Ph  193 ± 146 
132  CH2CH3 CH2CH2OH CH2CH2CH3    Ph  51.1 ± 13.3 
133  CH2CH3 CH2CH2OTHP (rac) CH2CH2CH3 CH2CH2CH3  Ph  517 ± 151 
134  CH2CH3 CH2-(2,2-dimethyl- 
1,3-dioxolane)(rac) 
CH2CH2CH3 CH2CH2CH3  Ph  2640 ± 390 
135  CH2CH3 CH2CH2F CH2CH2CH3 CH2CH2CH3  Ph  55.1 ± 8.2 
136  CH2CH3 CH2CF3 CH2CH2CH3 CH2CH2CH3  Ph  18.1 ± 2.2 
137  CH2CH3 CH2CH2CF3 CH2CH2CH3 CH2CH2CH3  Ph  82.8 ± 27.0 
138  CH2CH3 CH2CH3 CH2CH2OH CH2CH2CH3  Ph  262 ± 57 
139  CH2CH3 CH2CH3 CH2CH2SCOCH3 CH2CH2CH3  Ph  124 ± 29 
140  CH2CH3 CH2CH3 CH2CH2CH2F CH2CH2CH3  Ph  59.9 ± 17.1 
141  CH2CH3 CH2CH3 CH2CH2CH2OH CH2CH2CH3  Ph  169 ± 61 
142  CH2CH3 CH2CH3 CH2CH2CH3 CH2CH2CH2F  Ph  9.67 ± 3.34 
143  CH2CH3 CH2CH3 CH2CH2CH3 CH2CF2CF3  Ph  446 ± 119 
144  CH2CH3 CH2CH3 CH2CH2CH3 CH2CH2CH3  2-F-Ph  23.0 ± 6.8 
145  CH2CH3 CH2CH3 CH2CH2CH3 CH2CH2CH3  3-F-Ph  28.9 ± 10.8 
146  CH2CH3 CH2CH3 CH2CH2CH3 CH2CH2CH3  4-F-Ph  31.1 ± 9.24 
147  CH3 CO2CH3 2-CF3Ph NO2 CH3 23500  ±  600  
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Table 3. Structures and affinity  values at the human adenosine A3 receptor of 
triazoloquinazoline derivatives 
 
O
N N
N
N
Cl
N
R1 H
R2
148-161
O
N N
N
N
Cl
O
R3
162, 163
O
N N
N
N
Cl
N
R1 H
164-192
 
 
Comp. R1  R2  R3  Ki (nM ± SEM) 
148  H  H    13.8 ± 2.4 
149  COCH3  H    13.9 ± 2.5 
150  COCH2CH3  H    7.66 ± 3.03 
151  CO(CH2)2CH3  H    14.6 ± 2.8 
152  CO(CH2)3CH3  H    21.5 ± 6.2 
153  COC(CH3)3  H    244 ± 6 
154  COOC(CH3)3  H    82.5 ± 23.3 
155  CO(CH2)3NH-Boc  H    32.9 ± 1.7 
156  CO(CH2)3NH2  H    80.8 ± 7.4 
157  COPh  H    3.03 ± 1.73 
158  CO(3-I-Ph)  H    23.8 ± 5.2 
159  COCH2Ph  H    0.65 ± 0.25 
160  H  Br    64.0 ± 13.1 
161  COPh  Br    856 ± 156 
162      H  260 ± 87 
163     CH2CH2CH3  1813 ± 720 
164  COCH2-Ph      0.65 ± 0.25 
165  CH2-Ph      42.5 ± 6.91 
166   COCH2-(4-CH3OPh)    14.4 ± 3.2 
167   COCH2-(4-NH2-3-I-Ph)    49.3 ± 17.9 
168   COCH2-(4-NH2-Ph)    3.56 ± 1.24 
169   COCH2-(-3-I-Ph)    882 ± 242 
170   COCH2-(-4-I-Ph)    62.9 ± 13.0 
171   COCH2-(-3-Cl-Ph)    32.1 ± 11.3 
172   ( S)-COCH(CH3)(Ph)    0.468 ± 0.111 
173   COCH(Ph)2    0.586 ± 0.196 
174   COC(CH3)(Ph)2    194 ± 42 
175   COCH2CH2-Ph    23.6 ± 7.3 
176   COCH=CH-Ph  (trans)    72.1 ± 15.6 
177    L-COCH(CH3)(NH-Boc)    82.9 ± 2.7 
178   CO(CH2)2-NH-Boc    6.71 ± 0.67 
179   CO(CH2)3-NH-Boc   32.9 
180   CO(CH2)4-NH-Boc    22.0 ± 3.1  
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181   CO(CH2)5-NH-Boc    33.8 ± 10.2 
182   CO(CH2)6-NH-Boc    53.7 ± 31.0 
183    L-COCH(CH3)(NH2)    1200 ± 4.60 
184   CO(CH2)2-NH2    874 ± 4 
185   CO(CH2)3-NH2    80.8 ± 7.4 
186   CO(CH2)4-NH2    57.9 ± 20.8 
187   CO(CH2)5-NH2    213 ± 27 
188   CO(CH2)6-NH2    346 ± 77 
189   CO(CH2)4-COOBn    44.7 ± 14.1 
190   CO(CH2)2-COOCH3    55.1 ± 8.6 
191   CO(CH2)6-COOCH3    59.0 ± 14.1 
192   CO(CH2)3-COOH    81.3 ± 11.0 
 
 
Table 4. Structures and affinity  values at the human adenosine A3 receptor of 
imidazopurinone derivatives 
 
N
N
N
N
N
O
R8
R1
R2
R4
193-198  
Comp.  R1 R2 R4 R8 Ki (µM ± SEM) 
193  CH3  Ph  H  H  0.047 ± 0.0048 
194  CH3 Ph CH3  H  3.33 ± 0.72 
195  H Ph  CH3 CH2CH3 (R)  0.0023 ± 0.001 
196  H Ph  CH3 CH2CH3 (S)  0.0098 ± 0.0038 
197  Ph CH2=CH-Ph CH3 CH2CH3 (R)  1.70 ± 0.48 
198  H CH2=CH-Ph CH3 CH2CH3 (R)  0.64 ± 0.199 
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Table 5. Structures and affinity  values at the human adenosine A3 receptor of 
pyrazolo-triazolo-pyrimidine derivatives 
 
N N
N
N
N
H R1
O
Cl
236-238
N
N
N
N
N
N
R
N
H R1
O
199-235, 239-302
 
Comp. R  R1 pKi nM  
199  H H  -2.54 
200  H 4-OCH3-Ph-NHCO 0.85 
201  H 3-Cl-Ph-NHCO  0.30 
202  H H  -2.48 
203  CH3 4-OCH3-Ph-NHCO 0.70 
204  CH3 3-Cl-Ph-NHCO  0.39 
205  CH2CH3 H  -2.52 
206  CH2CH3 4-OCH3-Ph-NHCO 0.22 
207  CH2CH3 3-Cl-Ph-NHCO  -0.20 
208  CH2CH2CH3 H  -2.60 
209  CH2CH2CH3 4-OCH3-Ph-NHCO 0.10 
210  CH2CH2CH3 3-Cl-Ph-NHCO  0.04 
211  CH2CH=CH2 4-OCH3-Ph-NHCO 0.32 
212  CH2CH2CH2CH3 H  -2.78 
213  CH2CH2CH2CH3 4-OCH3-Ph-NHCO 0.49 
214  CH2CH2CH2CH3 3-Cl-Ph-NHCO  0.22 
215  C(CH3)3 H  -3.06 
216  C(CH3)3 4-OCH3-Ph-NHCO 0.10 
217  CH2CH2CH(CH3)2 3-Cl-Ph-NHCO  -0.44 
218  CH2CH2CH(CH3)2 H  -2.85 
219  CH2CH2CH(CH3)2 4-OCH3-Ph-NHCO -1.48 
220  CH2CH2CH(CH3)2 3-Cl-Ph-NHCO  -1.60 
221  CH2CH2C=(CH3)2 H  -2.91 
222  CH2CH2C=(CH3)2 4-OCH3-Ph-NHCO -1.60 
223  CH2CH2C=(CH3)2 3-Cl-Ph-NHCO  -1.74 
224  PhCH2CH2 H  -2.45 
225  PhCH2CH2 4-OCH3-Ph-NHCO 0.00 
226  PhCH2CH2 3-Cl-Ph-NHCO  -0.90 
227  PhCH2CH2CH2 H  -2.93 
228  PhCH2CH2CH2 4-OCH3-Ph-NHCO -1.60 
229  PhCH2CH2CH2 3-Cl-Ph-NHCO  -1.78 
230  2,4,5-Br3-PhCH2CH2CH2 H  -3.65 
231  2,4,5-Br3-PhCH2CH2CH2 4-OCH3-Ph-NHCO -1.40 
232  2,4,5-Br3-PhCH2CH2CH2 3-Cl-Ph-NHCO  -1.85  
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233  2-(α-naphthyl)ethyl H  -3.53 
234  2-(α-naphthyl)ethyl 4-OCH3-Ph-NHCO -1.20 
235  2-(α-naphthyl)ethyl 3-Cl-Ph-NHCO  -1.71 
236   H  -1.93 
237   4-OCH3-Ph-NHCO 0.85 
238   3-  Cl-Ph-NHCO  0.72 
239  CH3 Ph-NH-CO  0.80 
240  CH3 3,4-Cl2-Ph-NH-CO -0.53 
241  CH3 3,4-O-CH2O-Ph-NH-CO 0.62 
242  CH3 4-NO2-Ph-NH-CO 0.37 
243  CH3 4-CH3-Ph-NH-CO 0.51 
244  CH3 4-Br-Ph-NH-CO  0.34 
245  CH3 4-F-Ph-NH-CO  0.47 
246  CH3 4-CF3-Ph-NH-CO 0.13 
247  CH3 2-OCH3-Ph-NHCO 0.15 
248  CH3 3-OCH3-Ph-NHCO 0.10 
249  CH3 2-Cl-Ph-NHCO  0.04 
250  CH3 4-Cl-Ph-NHCO  0.54 
251  CH2CH3 Ph-NH-CO  0.74 
252  CH2CH3 3,4-Cl2-Ph-NH-CO -0.48 
253  CH2CH3 3,4-O-CH2O-Ph-NH-CO 0.57 
254  CH2CH3 4-NO2-Ph-NH-CO 0.19 
255  CH2CH3 4-CH3-Ph-NH-CO 0.85 
256  CH2CH3 4-Br-Ph-NH-CO  0.43 
257  CH2CH3 4-F-Ph-NH-CO  0.07 
258  CH2CH3 4-CF3-Ph-NH-CO 0.01 
259  CH2CH3 2-OCH3-Ph-NHCO 0.25 
260  CH2CH3 3-OCH3-Ph-NHCO 0.07 
261  CH2CH3 2-Cl-Ph-NHCO  0.52 
262  CH2CH3 4-Cl-Ph-NHCO  0.70 
263  CH2CH2CH3 Ph-NH-CO  0.82 
264  CH2CH2CH3 3,4-Cl2-Ph-NH-CO -0.40 
265  CH2CH2CH3 3,4-O-CH2O-Ph-NH-CO 0.52 
266  CH2CH2CH3 4-NO2-Ph-NH-CO 0.09 
267  CH2CH2CH3 4-CH3-Ph-NH-CO 0.40 
268  CH2CH2CH3 4-Br-Ph-NH-CO  0.35 
269  CH2CH2CH3 4-F-Ph-NH-CO  0.54 
270  CH2CH2CH3 4-CF3-Ph-NH-CO 0.29 
271  CH2CH2CH3 2-OCH3-Ph-NHCO 0.47 
272  CH2CH2CH3 3-OCH3-Ph-NHCO 0.40 
273  CH2CH2CH3 2-Cl-Ph-NHCO  0.15 
274  CH2CH2CH3 4-Cl-Ph-NHCO  0.47 
275  CH2CH2CH2CH3 3,4-Cl2-Ph-NH-CO 0.68 
276  CH2CH2CH2CH3 3,4-O-CH2O-Ph-NH-CO 0.57 
277  CH2CH2CH2CH3 4-NO2-Ph-NH-CO 0.30 
278  CH2CH2CH2CH3 4-CH3-Ph-NH-CO 0.26 
279  CH2CH2CH2CH3 4-Br-Ph-NH-CO  0.68 
280  CH2CH2CH2CH3 4-F-Ph-NH-CO  0.04 
281  CH2CH2CH2CH3 4-CF3-Ph-NH-CO 0.10 
282  CH2CH2CH2CH3 2-OCH3-Ph-NHCO 0.14 
283  CH2CH2CH2CH3 3-OCH3-Ph-NHCO 0.24 
284  CH2CH2CH2CH3 2-Cl-Ph-NHCO  0.22 
285  CH2CH2CH2CH3 4-Cl-Ph-NHCO  0.07  
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286  CH2CH2CH2CH3 Ph-NH-CO  0.37 
287  CH3 PhCH2-CO 0.09 
288  CH2CH3 PhCH2-CO -0.01 
289  CH2CH2CH3 PhCH2-CO 0.00 
290  CH2CH2CH2CH3 PhCH2-CO 0.05 
291  PhCH2CH2 CONHCH(CH3)2 -0.95 
292  PhCH2CH2 CONHC(CH3)3 -0.69 
293  CH2CH2CH(CH3)2 CONHCH(CH3)2 -1.81 
294  CH2CH2CH(CH3)2 CONHC(CH3)3 -1.59 
295  CH2CH2CH3 CONHCH(CH3)2 -1.32 
296  CH2CH2CH3 CONHC(CH3)3 -1.18 
297  PhCH2CH2CH2 CONHCH(CH3)2 -1.74 
298  PhCH2CH2CH2 CONHC(CH3)3 -1.81 
299  PhCH2CH2 CO(CH3)3NHCOOC(CH3)3 -0.17 
300  CH2CH2CH(CH3)2 CO(CH3)3NHCOOC(CH3)3 -0.39 
301  CH2CH2CH3 4-SO3-Ph-NH-CO -1.48 
302  CH2CH2CH(CH3)2 4-CH3-Ph-NH-CO -0.87 
 
 
Table 6. Structures and affinity  values at the human adenosine A3 receptor of 
1,2,4-triazolo[4,3-a]quinoxalinone derivatives 
 
N H
N
N
N
O
CH3
331
N
N
N
N
O
O
R1
R
325-330, 332-336
N
N
N
N
N
H R1
O
R
303-324
 
Comp. R  R1  Ki (nM ± SEM) 
303  3-CH3  H  28.5 ± 1.9 
304  4-CH3  H  48.3 ± 3.6 
305  3-F  H  157 ± 11 
306  4-OCH3  H  45.3 ± 3.8 
307  4-Cl  H  329 ± 28 
308  H  cyclohexyl  506 ± 43 
309  3-CH3  cyclohexyl  548 ± 3 
310  3-F  cyclohexyl  44.2 ± 3.5 
311  4-Cl  cyclohexyl  56.1 ± 4.2 
312  H  cyclopentyl  55.4 ± 4.2 
313  3-CH3  cyclopentyl  27.5 ± 1.19 
314  3-F  cyclopentyl  173 ± 14 
315  H PhCH2  1700 ± 138  
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316  H PhCH2CH2  201 ± 14 
317  H PhCH2CH2CH2  40.9 ± 3.3 
318  H (Ph)2CHCH2  1020 ± 99 
319  H COCH3  2 ± 0.13 
320  H COCH2CH3  15.8 ± 1.2 
321  H  COPh  1.47 ± 0.11 
322  H PhCH2CO  3.75 ± 0.20 
323  H  PhNHCO  276 ± 21 
324  H 4-OCH3-Ph-NHCO  960 ± 86 
325  H  H  80.0 ± 6.3 
326  3-CH3  H  91.0 ± 7.8 
327  4-CH3  H  25.0 ± 1.6 
328  3-F  H  63.0 ± 4.5 
329  4-OCH3  H  16 ± 1.2 
330  4-Cl  H  114 ± 9.7 
331      197 ± 4.2 
332  H CH3  36.6 ± 2.5 
333  4-CH3 CH3  504 ± 43 
334  4-Cl CH3  137 ± 11.8 
335  H CH2CH2CH3  1246 ± 110 
336  H  CH2C≡CH  479 ± 34  
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Table 7. Structures and affinity values at the human adenosine A3 receptor of quinazoline and isoquinoline derivatives 
N
N
N H O
R2
R3
R4
R5
R6
338-349
N
X R1
N H O
N H
R2
R3
R4
359-377
N
X
Y
N H O
R
337, 350-358
 
Comp. X  Y  R  R1  R2  R3  R4  R5 R6 Ki (µM ± SEM) 
337  CH N  CH3              13 ± 1.9 
338          H Cl H  H  H  0.77  ±  0.50 
339         H CH3  H  H  H  0.24 ± 0.084 
340         H  OCH3  H  H  H  0.15 ± 0.023 
341          H  Cl  Cl  H  H  0.21 ± 0.049 
342          H  H  Cl  H  H  0.20 ± 0.049 
343         H  H CH3  H  H  0.096 ± 0.026 
344         CH3 H  H H  CH3  2.6 ± 0.74 
345         CH3 H  H  CH3  H  0.43 ± 0.10 
346         CH3 H CH3  H  H  0.36 ± 0.13 
347         H CH3 CH3  H  H  0.069 ± 0.021 
348         H CH3 H  CH3  H  0.32 ± 0.13  
 
98
349         H  OCH3 OCH3  H  H  0.31 ± 0.12 
350  N N  CH3              11 ± 5.4 
351  N N  CF3              86 ± 5.2 
352  N N 4-OCH3Ph              0.15 ± 0.12 
353  CH  N  Ph              0.20 ± 0.04 
354  CH  CH  Ph              1.2 ± 0.3 
355  N  N  Ph              0.23 ± 0.02 
356  N  CH  Ph              0.24 ± 0.06 
357  CH CH 4-OCH3-Ph              3.0 ± 0.7 
358  N CH  4-OCH3-Ph    H  H  H      1.8 ± 0.8 
359  CH      2-pyridyl  H  H  H      0.076 ± 0.01 
                  
 
 
Comp. X  Y  R  R1  R2  R3  R4  R5 R6 Ki (nM ± SEM) 
360  N      H  H  H  H      1180 ± 50 
361  N      2-pyridyl  H  H  H      495 ± 167 
362  N     C(CH3)3 H  H  H      78700  ±  57000 
363  N      Ph  H  H  H      287 ± 106 
364  N      3-pyridyl  H  H  H      50.9 ± 4.3 
365  N      4-pyridyl  H  H  H      336 ± 58 
366  N     6-CH3-2-pyridyl  H  H  H      264 ± 29 
367  N     N
N
CH3
CH3  
H  H  H      1260 ± 540  
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368  N    
O
 
H  H  H      257 ± 22 
369  N     N(CH2CH3)2  H  H  H      178 ± 55 
370  N     N
 
H  H  H      82.3 ± 15 
371  N     Ph  H OCH3  H      2040 ± 1890 
372  N     Ph  OCH3  H  H      87.3 ± 36.8 
373  N      Ph  Cl  H  H      220 ± 45 
374  N     Ph  CH3  H  H      1115 ± 31.3 
375  N     3-pyridyl  OCH3  H  H      4.03 ± 0.46 
376  N     3-pyridyl  CH3  H  H      23.9 ± 9.4 
377  N     2-pyridyl  OCH3  H  H      28.2 ± 7.3   100
Table 8. Structures and affinity  values at the human adenosine A3 receptor of 
thiazole and thiadiazole derivatives 
 
Y
X
S N
N
H
R
O
N
S N
N
H
R
O
Y
X
S N
N
H
R
O
378-395 396-400 401-432  
Comp. R  X  Y  Ki (µM ± SEM) 
378  4-OCH3-Ph  CH  CH  0.67 ± 0.10 
379  Ph  CH  N  3.4 ± 1 
380  4-Cl-Ph  CH  N  3.2 ± 2 
381  4-I-Ph  CH  N  2.8 ± 1 
382  4-CH3-Ph  CH  N  3.2 ± 0.3 
383  4-OCH3-Ph  CH  N  1.8 ± 0.6 
384  3,4-diCl-Ph  CH  N  1.5 ± 1 
385  3-Cl-Ph  CH  N  4.6 ± 1 
386  4-NO2-Ph  CH  N  3.5 ± 0.9 
387  4-OCH(CH3)-Ph  CH  N  3.7 ± 0.7 
388  cyclopentyl  CH  N  2.1 ± 0.8 
389  Ph  N  CH  0.41 ± 0.1 
390  4-Cl-Ph  N  CH  0.52 ± 0.3 
391  4-I-Ph  N  CH  1.1 ± 0.9 
392  4-CH3-Ph  N  CH  0.14 ± 0.03 
393  3-CH3-4-OCH3-Ph N  CH 0.58  ±  0.2 
394  4-OH-Ph  N  CH  0.13 ± 0.01 
395  4-OCH2CO2HPh  N  CH  1.2 ± 0.81 
396  cyclohexyl  N  CH  16 ± 8 
397  4-OCH3-cyclohexyl (trans)  N  CH  1.7 ± 0.6 
398  4-OCH3-cyclohexyl (cis)  N  CH  5.3 ± 2 
399  4-OH-cyclohexyl (trans)  N  CH  1.9 ± 0.4 
400  4-OH-cyclohexyl (cis)  N  CH  2.7 ± 0.6 
 
 
      
Comp. R  X  Y  Ki (nM ± SEM) 
401  4-OCH3-Ph  N  H  82 ± 4 
402  CH3  CH  H  18.3 ± 4.2 
403  CO(CH3)3  CH  H  5100 ± 1130 
404  CH2CN  CH  H  204 ± 17   101
405  CH3  CH  4-Cl  50.9 ± 23.5 
406  CH2-Ph CH  4-Cl  100 
407  CH3 CH  4-OCH3  3.0 ± 0.8 
408  CH3 CH  3-OCH3  4.1 ± 1.8 
409  CH3 CH  2-OCH3  82 ± 21 
410  CF3 CH  4-OCH3  530 ± 91 
411  CH2CH3 CH  4-OCH3  2.4 ± 0.6 
412  CH2CH2CH3 CH  4-OCH3  7.8 ± 1.5 
413  CH(CH3)2 CH  4-OCH3  16.3 ± 4.1 
414  CH2CN CH  4-OCH3  24.3 ± 3.9 
415  C(CH3)3 CH  4-OCH3  31.9 ± 4.2 
416  CO(CH3)3 CH  4-OCH3  3260 ± 340 
417  Ph CH  4-OCH3  28.7 ± 3.3 
418  CH2-Ph CH  4-OCH3  14.2 ± 3.0 
419  CH2CH2-Ph CH  4-OCH3  29.1 ± 9.3 
420  4-CH3-PhCH2 CH  4-OCH3  1160 ± 190 
421  4-CH3-PhCH2CH2 CH  4-OCH3  28.6 ± 7.3 
422  (Ph)2CH CH  4-OCH3  526 ± 193 
423  (Ph)2CHCH2 CH  4-OCH3 400 
424  2-furan CH  4-OCH3  31.5 ± 1.3 
425  thiophene-2-CH2 CH  4-OCH3  32.3 ± 7.1 
426  2-thiophene CH  4-OCH3  69.3 ± 10.0 
427   CH  4-OCH3  373 ± 74 
428  CH3  N  H  2.3 ± 0.2 
429  CH2-Ph  N  H  79 ± 26 
430  CH3 N  4-OCH3  0.79 ± 0.18 
431  CH2-Ph N  4-OCH3  23.8 ± 0.3 
432  CH2CH3 N  4-OCH3  1.13 ± 0.14 
 
 
Table 9. Structures and affinity values at the human adenosine A3 receptor of 9-
ethylpurine derivatives 
 
N
N N
N
Y
X
z
433-449  
Comp. X  Y  Z Ki (µM) 
433  H NH2 Br  27.8 
434  H NH2 O-(CH2)2-Ph 36.2 
435  H NH2 NH-(CH2)2-Ph 49.4 
436  H NH2  C≡C-(CH2)2-Ph  3.20 
437  H NH2  C≡C-(CH2)3-CH3  0.62   102
438  O-(CH2)2-Ph NH2 H  7.15 
439  NH-(CH2)2-Ph NH2 H  3.15 
440  C≡C-(CH2)2-Ph  NH2 H  4.05 
441  C≡C-(CH2)3-CH3  NH2 H  2.30 
442  H O-(CH2)2-Ph H 22.1 
443  H NH-(CH2)2-Ph H  10.8 
444  H  C≡C-(CH2)2-Ph  H 39.3 
445  H  C≡C-(CH2)3-CH3  H 39.2 
446  H O-(CH2)2-Ph Br 60.9 
447  H NH-(CH2)2-Ph Br  2.44 
448  H  C≡C-(CH2)2-Ph  Br 44.7 
449  H  C≡C-(CH2)3-CH3  Br 19.0 
 
 
Table 10. Structures and affinity values at the human adenosine A3 receptor of 2-
arylpyrazolo[3,4-c]quinoline derivatives 
 
N
N
N R2
O
R1
R
N
N
N
NH
R1
R2
R
450-459 460-483  
Comp. R R1  R2  Ki (nM ± SEM) 
450  H  H  H  30.8 ± 2.6 
451  H  Cl  H  44.1 ± 3.2 
452  2-CH3  H  H  79.2 ± 6.3 
453  3-CH3  H  H  5.0 ± 0.4 
454  4-CH3  H  H  3.2 ± 0.2 
455  3-F  H  H  45.3 ± 3.9 
456  4-OCH3  H  H  3.2 ± 0.2 
457  4-Cl  H  H  2.9 ± 0.1 
458  H H  CH3  118 ± 10 
459  H H  CH2CH2CH3  68.4 ± 5.3 
460  H  H  H  551 ± 34 
461  H  Cl  H  309 ± 23 
462  2-CH3  H  H  3600 ± 280 
463  3-CH3  H  H  99.3 ± 7.8 
464  4-CH3  H  H  188 ± 15 
465  3-F  H  H  788 ± 69 
466  4-OCH3  H  H  90.2 ± 7.3   103
467  4-Cl  H  H  150 ± 12 
468  H  H  cyclohexyl  707 ± 53 
469  H  Cl  cyclohexyl  2128 ± 170 
470  3-CH3  H  cyclohexyl  44.1 ± 3.7 
471  4-CH3  H  cyclohexyl  115 ± 9.1 
472  3-F  H  cyclohexyl  155 ± 12 
473  4-Cl  H  cyclohexyl  56.5 ± 4.5 
474  H  H  cyclopentyl  60.5 ± 4.8 
475  2-CH3  H  cyclopentyl  152 ± 13 
476  3-CH3  H  cyclopentyl  22.3 ± 1.6 
477  3-F H  CH2-Ph  35.8 ± 2.8 
478  H H  CH2CH2-Ph  32.9 ± 2.3 
479  H H COCH3  48.2 ± 3.7 
480  H  H  COPh  2.1 ± 0.1 
481  H H  COCH2-Ph  9.9 ± 0.8 
482  H  H  CONHPh  108 ± 9.6 
483  H H  CONHCH2-Ph  8.3 ± 0.7 
 
 
Table 11. Structures and affinity values at the human adenosine A3 receptor of 1-
benzyl-1H,3H-pyrido[2,1-f]purine-2,4-dione derivatives 
 
N
N N
N
O
R2
O
R1
N
N N
N
R2
O
O
R1
484-500
501-503
 
Comp. R  R1  Ki (nM ± SEM) 
484  H  H  370 ± 40 
485  OCH3  H  210 ± 219 
486  C(CH3)3  H  555 ± 65 
487  Ph  H  200 ± 67 
488  H CH2CH2CH3  4.0 ± 0.3 
489  OCH3 CH2CH2CH3  10.0 ± 0.6 
490  C(CH3)3 CH2CH2CH3  950 ± 130 
491  Ph CH2CH2CH3  35 ± 13 
492  H CH2CH3  36 ± 7 
493  H CH2-cyclopropyl  4.2 ± 1.1 
494  H CH2CH(CH3)2  6.3 ± 2.2 
495  H CH2-cyclohexyl  114 ± 60 
496  H CH2CH=CH2  5.0 ± 1.8   104
497  H  CH2CH≡CH  14 ± 9 
498  H CH2CH=CHCOOCH3  1125 ± 293 
499  H CH2Ph  77 ± 32 
500  H 4-OCH3PhCH2  213 ± 61 
501  CH3 CH2CH2CH3  3020 ± 250 
502  4-OCH3PhCH2 CH2CH2CH3  8.3 ± 2.8 
503  3-CH3PhCH2 CH2CH2CH3  68 ± 34 
 
 
Table 12. Structures and affinity values at the human adenosine A3 receptor of 
xanthine and 9-deazaxanthine derivatives 
 
N
N
N
H
O
O
R1
R3
R8
515-516, 521
N
N N
N
H
O
O
R1
R3
O
R8
513, 514
N
N N
N
H
O
O
R1
R3
R8
504-510
N
N N
N
H
O
O
R1
R3
R8
511, 512
N
N
H
N
N
H
O
O
R1
O
O
N
N
R8
519, 520
N
N
H
N
N
H
O
O
R1
O
O
N
H
R8
517, 518
 
Comp. R1  R3  R8  Ki (nM ± SEM) 
504  CH2CH2CH3 CH2CH2CH3  cyclopentyl  795 ± 139 
505  CH2CH3  H  Ph  950 ± 32 
506  CH2CH2CH3  H  4-BrPh  173 ± 9 
507  CHC≡CH  H  4-BrPh  477 ± 1 
508  CH2CH2CH2CH3  H  4-COOHPh  4622 ± 323 
509  CH2CH2CH2CH3 H  4-(COOCH3)Ph  2857 ± 16 
510  CH2CH2CH3  H  6-COOH-2-naphthyl  1184 ± 169 
511  CH2CH2CH3  H  COOH  1217 ± 231 
512  CH2CH2CH3 H  COOCH3  1119 ± 147   105
513  CH2CH2CH2CH3  H  COOH  1192 ± 147 
514  CH2CH2CH3 H  COOCH3  80.6 ± 10.9 
515  CH3  H  Ph  2098 ± 299 
516  CH2CH2CH3  H  Ph  380 ± 17 
517  CH2CH2CH3   OHCH2CH2  422 ± 35 
518  CH2CH2CH2CH3    4-COOHPh  676 ± 224 
519  CH2CH2CH2CH3   PhCH2  475 ± 114 
520  CH2CH2CH2CH3   2-OCH3-Ph  102 ± 2 
521  CH2CH2CH3   Ph-4-O-CH2COOH  15 ± 2 
 
 
Table 13. Structures and affinity values at the human adenosine A3 receptor of 
pyrazolo[4,3-c]-1,2,4-triazolo[1,5-c]pyrimidine derivatives 
 
N N
N
N
N
N
O
R1 C H3
N
R2 H
N N
N
N
N
N
NH2 EtO
522-531
532
 
 
Comp. R1  R2  Ki (nM) 
522  NHCH2CH3 H 225 
523  SCH3 H  35 
524  S(CH2)2CH3 H  224 
525  NHCH2CH3 CONHPh-4-OCH3 14 
526  SCH3 CONHPh-4-OCH3 212 
527  SCH3 COCH2Ph-3,4-Medioxy 110 
528  NHCH2CH3 COCH2Ph-3,4-Medioxy 183 
529  NHPh-4-OH H  308 
530  NHCH2CH3·HCl H  25 
531  NHCH2CH3·HCl CONHPh-4-OCH3 9 
532     348 
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Table 14. Structures and affinity values at the human adenosine A3 receptor of 
pyrrolo[2,3-d]pyrimidine-4-amine derivatives 
 
N
N N
N
R2
N
H R3
CH3
CH3
R1
533-539  
 
Comp. R1  R2  R3  Ki (µM) 
533  H Ph  (R)-1-CH3-PhCH2 0.028 
534  (R)-1-CH3-PhCH2 4-Pyridyl  CH2=CHCOOCH3 2.64 
535  (R)-1-CH3-PhCH2 Ph  (R)-1-CH3-PhCH2 11.4 
536  (R)-1-CH3-PhCH2 Ph  cyclopentyl  8.65 
537  (R)-1-CH3-PhCH2 Ph  NH2CH2CH2 5.58 
538  (R)-1-CH3-PhCH2 4-Cl-Ph (R,S)-2-butan-1-ol 0.57 
539  cyclopentyl Ph  (R,S)-2-butan-1-ol 1.87 
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Appendix B 
 
A) Flavonoid derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for molecules belonging to the subTR used to build the 
model. 
 
Calculated  pKi Experimental  pKi Difference Compound 
5.3926 5.5017  -0.1090  1 
5.7711 5.9172  -0.1461  2 
6.2513 6.4389  -0.1876  3 
6.6333 6.4989  0.1343  5 
5.1490 5.5768  -0.4278  7 
5.7773 5.3161  0.4612  8 
5.3577 5.1385  0.2193  9 
5.1444 4.3002  0.8443  10 
5.6868 5.7721  -0.0853  12 
5.9463 6.1302  -0.1839  14 
4.3659 4.3002  0.0658  17 
5.5198 5.4685  0.0513  20 
5.1350 5.1739  -0.0390  30 
5.0848 5.8601  -0.7753  35 
4.9683 4.7905  0.1778  36 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
6.3636 6.1261  0.2375  4 
5.8172 4.9393  0.8779  13 
5.8736 5.4724  0.4012  34 
 
 
Descriptor space for flavonoid derivatives. 
 
Descriptor ZXS/ZXR MPCC HASA-2 
Min  0.8052 1.47e-3  0 
Max  0.8746 0.0287  5.7434 
 
All the TS molecules were within the descriptor space.   108
B) Pyridine and 1,4-dihydropyridine derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
 
Calculated  pKi Experimental  pKi Difference Compound 
7.5969 7.7235  -0.1266  124 
7.5969 7.6990  -0.1021  125 
6.7721 6.9626  -0.1905  130 
7.5969 7.7423  -0.1454  136 
6.7721 6.5817  0.1904  138 
7.5969 7.2226  0.3743  140 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
6.7721 6.7144  0.0577  131 
6.7721 6.7721  0.0000  141 
 
 
Descriptor space for pyridine and 1,4-dihydropyridine derivatives. 
 
Descriptor NO 
Min  3 
Max  7 
 
The two TS molecules were within the descriptor space. 
 
 
C) Triazoloquinazoline derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
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Calculated  pKi Experimental  pKi Difference Compound 
7.7902 7.8570  -0.0668  149 
7.7805 7.8356  -0.0551  151 
8.1624 8.1733  -0.0109  178 
7.7021 7.4828  0.2192  179 
7.5235 7.6576  -0.1341  180 
7.5187 7.4711  0.0476  181 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
7.7818 8.1158  -0.3340  150 
7.5175 7.2700  0.2475  182 
 
 
Descriptor space for triazoloquinazoline derivatives. 
 
Descriptor MPCN 
Min  -0.0707 
Max  -0.0667 
 
The two TS molecules fell outside the descriptor space. 
 
 
D) Imidazo[2,1-i]purin-5-one derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
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Calculated  pKi Experimental  pKi Difference Compound 
7.1384 7.3279  -0.1895  193 
5.4491 5.4776  -0.0284  194 
7.5347 8.0088  -0.4740  196 
5.6202 5.7696  -0.1493  197 
7.0351 6.1938  0.8413  198 
 
 
Table illustrating the calculated pKi, the experimental pKi and the difference 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
7.5347 8.6383  -1.1035  195 
 
 
Descriptor space for imidazo[2,1-i]purin-5-one derivatives. 
 
Descriptor ACIC(1) 
Min  0.3979 
Max  0.6074 
 
The TS molecule was within the descriptor space. 
 
 
E) Pyrazolo triazolo pyrimidine derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
 
Calculated  pKi Experimental  pKi Difference Compound 
6.1170 6.1500  -0.0330  218 
8.7522 7.5200  1.2322  219 
9.0769 9.3700  -0.2931  242 
9.6905 9.5100  0.1805  243 
8.9619 9.1900  -0.2281  254 
9.5594 9.8500  -0.2906  255   111
9.5594 9.4300  0.1294  256 
8.8539 9.0900  -0.2361  266 
9.4367 9.4000  0.0367  267 
9.4367 9.3500  0.0867  268 
8.7522 9.2600  -0.5078  278 
9.3217 9.6800  -0.3583  279 
9.3217 9.0400  0.2817  280 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
9.6905 9.3400  0.3505  244 
8.2565 7.5200  0.7365  301 
8.8539 8.1300  0.7239  302 
 
 
Descriptor space for pyrazolo triazolo pyrimidine derivatives. 
 
Descriptor RNBR  CIC(2) 
Min  0 0.0870 
Max  0.0345 0.1935 
 
Molecule 301 did not fall within the descriptor space. 
 
F1) 1,2,4-Triazolo[4,3-a]quinoxalin-1-one derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
 
Calculated  pKi Experimental  pKi Difference Compound 
7.0255 7.5452  -0.5196  303 
7.0255 6.8041  0.2214  305 
6.9811 7.3439  -0.3628  306 
7.0217 6.4828  0.5389  307 
6.8301 6.2958  0.5342  308 
6.7828 6.2612  0.5216  309 
6.7775 7.2510  -0.4736  311   112
6.8779 7.2565  -0.3786  312 
6.8337 7.5607  -0.7270  313 
6.8337 6.7620  0.0717  314 
6.7654 5.7696  0.9958  315 
6.6935 6.6968  -0.0033  316 
6.6141 7.3883  -0.7741  317 
6.3468 5.9914  0.3554  318 
8.5852 8.6990  -0.1138  319 
8.5443 7.8013  0.7430  320 
8.3517 8.8327  -0.4810  321 
8.2778 8.4260  -0.1482  322 
6.3617 6.5591  -0.1974  323 
6.2151 6.0177  0.1974  324 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
7.0217 7.3161  -0.2944  304 
6.7828 7.3546  -0.5717  310 
 
 
Descriptor space for 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives. 
 
Descriptor NDB  NN  WI 
Min  3 5  964 
Max  4 6  3.61e+3 
 
The two TS molecules were within the descriptor space. 
 
 
F2) 1,2,4-Triazolo[4,3-a]quinoxalin-1-one derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
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Calculated  pKi Experimental  pKi Difference Compound 
7.0798 7.0969  -0.0171  325 
7.0623 7.0410  0.0213  326 
7.0623 7.2007  -0.1384  328 
7.6858 7.7959  -0.1100  329 
7.0623 6.9431  0.1192  330 
6.5788 6.7055  -0.1268  331 
7.0798 7.4365  -0.3568  332 
6.8182 6.2976  0.5207  333 
7.0623 6.8633  0.1990  334 
5.7934 5.9045  -0.1111  335 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
7.0623 7.6021  -0.5398  327 
5.7934 6.3197  -0.5262  336 
 
 
Descriptor space for 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives. 
 
Descriptor CIC(0) RNO 
Min  48.7940 0.0455 
Max  60.3184 0.1250 
 
The two TS molecules were within the descriptor space. 
 
 
G1) Isoquinoline and quinazoline derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
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Calculated  pKi Experimental  pKi Difference Compound 
6.8177 6.6198  0.1979  339 
6.6945 6.8239  -0.1294  340 
6.6773 6.6778  -0.0005  341 
6.6638 6.6990  -0.0352  342 
6.8395 6.5086  0.3308  349 
5.9437 5.9281  0.0156  360 
6.0234 5.8996  0.1238  367 
6.9283 6.7496  0.1787  369 
6.7325 7.0846  -0.3521  370 
6.7140 7.0590  -0.3450  372 
6.6729 6.6576  0.0154  373 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
6.6936 6.1135  0.5800  338 
6.5602 6.5421  0.0181  363 
6.7423 5.6904  1.0519  371 
 
 
Descriptor space for isoquinoline and quinazoline derivatives. 
 
Descriptor HACA-2/SQRT 
Min  0.0409 
Max  0.0659 
 
All the TS molecules were within the descriptor space. 
 
 
G2) Isoquinoline and quinazoline derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
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Calculated  pKi Experimental  pKi Difference Compound 
5.1683 4.8861  0.2823  337 
6.2827 6.6198  -0.3371  339 
7.1966 6.8239  0.3727  340 
6.7071 6.6778  0.0293  341 
6.7223 6.6990  0.0233  342 
6.6192 7.0177  -0.3985  343 
6.0550 5.5850  0.4700  344 
6.5403 6.3665  0.1738  345 
6.6208 6.4437  0.1771  346 
6.4559 7.1612  -0.7052  347 
6.3752 6.4949  -0.1197  348 
6.9084 6.5086  0.3998  349 
5.0480 4.9586  0.0894  350 
3.9990 4.0655  -0.0665  351 
7.1360 6.8239  0.3121  352 
6.4461 6.6990  -0.2529  353 
6.4152 5.9208  0.4944  354 
6.2689 6.6383  -0.3694  355 
6.3643 6.6198  -0.2554  356 
7.0215 7.1024  -0.0809  357 
6.9128 7.5686  -0.6558  358 
6.9712 7.1192  -0.1480  359 
6.0008 5.9281  0.0727  360 
6.6972 6.3054  0.3918  361 
6.8171 7.2933  -0.4762  364 
6.8373 6.4737  0.3637  365 
6.9630 6.5784  0.3846  366 
6.9214 5.8996  1.0218  367 
6.8148 6.5901  0.2247  368 
6.3716 6.7496  -0.3779  369 
6.8295 7.0846  -0.2551  370 
7.5588 7.0590  0.4998  372 
6.8940 6.6576  0.2364  373 
6.9065 6.9393  -0.0328  374 
7.5918 8.3947  -0.8029  375 
6.9236 7.6216  -0.6980  376 
7.5626 7.5498  0.0129  377 
 
 
Table illustrating the calculated pKi, the experimental pKi and the difference 
between the two values for the molecule belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
5.8540 4.1040  1.7500  362 
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Descriptor space for isoquinoline and quinazoline derivatives. 
 
Descriptor KSI(2) RPCS RNCG  NR CIC(1) 
Min  5.1441 0 0.1226  3  46.2647 
Max  8.2804 1.6832 0.2846  4  119.9063 
 
The TS molecule was within the descriptor space. 
 
 
H1) Thiazole derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
 
Calculated  pKi Experimental  pKi Difference Compound 
6.9356 7.1192  -0.1836  378 
5.7530 5.6198  0.1332  381 
5.6690 5.7959  -0.1269  382 
5.5465 5.4949  0.0516  383 
5.4891 5.7696  -0.2804  385 
5.6255 5.8239  -0.1984  386 
5.5319 5.2366  0.2953  387 
6.3454 6.0362  0.3092  388 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
5.7530 6.6990  -0.9459  380 
5.5389 5.7959  -0.2569  384 
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Descriptor space for thiazole derivatives. 
 
Descriptor AIC(2) 
Min  3.8355 
Max  4.5427 
 
The two TS molecules where within the descriptor space. 
 
 
H2) Thiadiazole derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
 
Calculated  pKi Experimental  pKi Difference Compound 
8.0163 7.5086  0.5076  389 
7.2313 7.3872  -0.1559  390 
6.1311 5.9586  0.1725  391 
7.3364 7.5229  -0.1865  392 
7.7704 8.1367  -0.3663  394 
7.5234 7.4949  0.0286  401 
 
 
Table illustrating the calculated pKi, the experimental pKi and the difference 
between the two values for the molecule belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
6.8731 7.0000  -0.1269  395 
 
 
 
 
 
 
 
   118
Descriptor space for thiadiazole derivatives. 
 
Descriptor KHI(2) 
Min  5.8132 
Max  6.6548 
 
Molecule 395 did not fall within the descriptor space. 
 
 
I1) 9-Ethylpurine derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
 
Calculated  pKi Experimental  pKi Difference Compound 
4.4986 4.5560  -0.0573  433 
4.4986 4.4413  0.0573  434 
5.4949 5.4949  0.0000  436 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
4.4986 4.3063  0.1924  435 
5.4949 6.2076  -0.7128  437 
 
 
Descriptor space for 9-ethylpurine derivatives. 
 
Descriptor NTB 
Min  0 
Max  1 
 
The two TS molecules where within the descriptor space. 
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I2) 9-Ethylpurine derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
 
Calculated  pKi Experimental  pKi Difference Compound 
4.4544 4.6556  -0.2012  442 
5.2896 4.9666  0.3230  443 
4.4544 4.4056  0.0488  444 
4.4544 4.4067  0.0477  445 
5.2896 5.6126  -0.3230  447 
4.4544 4.3497  0.1047  448 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
4.4544 4.2154  0.2390  446 
4.4544 4.7212  -0.2668  449 
 
Descriptor space for 9-ethylpurine derivatives. 
 
Descriptor NN 
Min  4 
Max  5 
 
The two TS molecules were within the descriptor space. 
 
 
L) 2-Arylpyrazolo[3,4-c]quinoline derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
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Calculated  pKi Experimental  pKi Difference Compound 
7.2780 7.5114  -0.2334  450 
7.2780 7.3556  -0.0775  451 
7.2780 6.9281  0.3499  457 
6.5344 6.2588  0.2756  460 
6.5344 6.5100  0.0244  461 
6.5344 6.1506  0.3838  468 
6.5344 7.2182  -0.6838  474 
7.2780 7.3170  -0.0389  479 
8.6778 8.6778  0.0000  480 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
7.2780 7.1649  0.1131  459 
6.5344 5.6720  0.8624  469 
8.6778 8.0044  0.6734  481 
 
 
Descriptor space for 2-arylpyrazolo[3,4-c]quinoline derivatives. 
 
Descriptor NAB  NO 
Min  12 0 
Max  18 1 
 
All the TS molecules were within the descriptor space. 
 
 
M1) 1-Benzyl-1H,3H-pyrido[2,1-f]purine-2,4-dione derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
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Calculated  pKi Experimental  pKi Difference Compound 
7.2939 6.6778  0.6161  485 
6.7503 6.2557  0.4946  486 
6.1890 6.6990  -0.5099  487 
7.9469 8.3979  -0.4511  488 
7.2939 7.4437  -0.1498  492 
 
 
Table illustrating the calculated pKi, the experimental pKi and the difference 
between the two values for the molecule belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference  Compound 
5.8928 6.4318  -0.5390  484 
 
 
Descriptor space for 1-benzyl-1H,3H-pyrido[2,1-f]purine-2,4-dione derivatives. 
 
Descriptor AIC(2) 
Min  4.3074 
Max  4.4839 
 
Molecule 485 did not fall within the descriptor space. 
 
 
M2) 1-Benzyl-1H,3H-pyrido[2,1-f]purine-2,4-dione derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
 
Calculated  pKi Experimental  pKi Difference Compound 
7.2088 6.6990  0.5099  487 
7.9571 8.3979  -0.4409  488 
6.9272 8.0000  -1.0728  489 
5.9906 6.0223  -0.0317  490 
7.4774 8.2007  -0.7233  494 
6.7234 7.1135  -0.3901  499   122
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
6.5115 7.4559  -0.9444  491 
6.1518 6.6716  -0.5198  500 
 
 
Descriptor space for 1-benzyl-1H,3H-pyrido[2,1-f]purine-2,4-dione derivatives. 
 
Descriptor IC(0)  CIC(2) 
Min  50.8122 4 
Max  68.4213 22 
 
The two TS molecules were within the descriptor space. 
 
 
N) Xanthine and 9-deazaxanthine derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
 
Calculated  pKi Experimental  pKi Difference Compound 
5.9633 6.0996  -0.1363  504 
5.6128 6.0223  -0.4094  505 
6.5456 6.3215  0.2241  507 
5.7887 5.3352  0.4535  508 
5.7906 5.5441  0.2465  509 
5.9947 5.9266  0.0681  510 
6.0481 5.9147  0.1334  511 
6.0057 5.9512  0.0545  512 
5.7843 5.9237  -0.1394  513 
6.5398 7.0937  -0.5538  514 
5.9633 5.6782  0.2851  515 
6.5402 6.3747  0.1655  517 
5.7850 6.1701  -0.3850  518 
6.5935 6.3233  0.2702  519 
6.7145 6.9914  -0.2769  520 
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Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
6.5456 6.7620  -0.2164  506 
5.8957 6.4202  -0.5245  516 
6.9354 7.8239  -0.8885  521 
 
 
Descriptor space for xanthine and 9-deazaxanthine derivatives. 
 
Descriptor MPCN MPCC 
Min  -0.0933 7.59e-4 
Max  -0.0656 7.55e-3 
 
All the TS molecules were within the descriptor space. 
 
 
O) Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
 
Calculated  pKi Experimental  pKi Difference Compound 
7.1225 7.4559  -0.3335  523 
7.6597 7.8539  -0.1942  525 
7.1894 6.6737  0.5157  526 
6.7218 6.9586  -0.2368  527 
7.2409 6.7375  0.5034  528 
6.7937 6.5114  0.2823  529 
7.6612 7.6021  0.0592  530 
7.6597 8.0458  -0.3860  531 
6.2483 6.4584  -0.2101  532 
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Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
 
Calculated  pKi Experimental  pKi Difference Compound 
7.5534 6.6478  0.9056  522 
7.3314 6.6498  0.6817  524 
 
 
Descriptor space for pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives. 
 
Descriptor ABIC(1)  HACA-2 
Min  0.8229 0.7251 
Max  0.9016 1.1757 
 
Molecule 525 did not fall within the descriptor space. 
 
 
P) Pyrrolo[2,3-d]pyrimidine-4-amine derivatives 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the subTR used to build 
the model. 
 
Calculated pKi Experimental  pKi Difference Compound 
7.5554 7.5528  0.0026  533 
5.3092 5.5784  -0.2692  534 
5.2851 5.0630  0.2221  536 
5.2979 5.2534  0.0445  537 
 
 
Table illustrating the calculated pKi, the experimental pKi and the differences 
between the two values for the molecules belonging to the TS. 
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Calculated pKi Experimental  pKi Difference Compound 
5.2851 4.9431  0.3421  535 
5.3047 6.2441  -0.9394  538 
5.2958 5.7282  -0.4324  539 
 
 
Descriptor space for pyrrolo[2,3-d]pyrimidine-4-amine derivatives. 
 
Descriptor MPCN 
Min  -0.0997 
Max  -0.0847 
 
All the TS molecules were within the descriptor space. 
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Chapter 5 
 
Concluding Remarks 
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Over the last years, increasing number of applications of QSAR appeared in the 
literature, not only in lead finding and lead optimization, but also in other fields 
related to drug discovery, such as ADMET predictions. QSAR is also used in other 
research areas, not necessarily related to drugs, such as prediction of physico-
chemical constants of compounds or prediction of environmental parameters such 
as water pollution. 
Nevertheless, a number of questions are still open, for instance: 
-  Which are the applicability limits of a QSAR model, and how to recognize 
them in order to accurately estimate its level of reliability? 
-  What is the role of the model validation and what is the meaning of the 
statistical parameters? 
-  Is there (and what is) an optimal method for selecting a TR/TS couple? 
-  What is the meaning of concepts such as “over-fitting”, “interpolation”, 
“extrapolation”, etc.? 
-  How important are the size of the dataset and the structural variability of 
compounds comprised into it? 
These and other questions supplied the starting point of the work presented in this 
thesis. In particular, the attention was focused on characteristics that are usually 
intended as intrinsic “limitations”, or “pitfalls” of QSAR, and it was looked at them 
not under a negative point of view, but considering them just as the “boundaries” 
inside which a QSAR model can provide a reliable prediction. In order to achieve 
this purpose, each step of the process of QSAR model development was handled 
with an approach as much rational and rigorous as possible. The classic QSAR 
strategies were implemented with new protocols, as described in chapters 3 and 4 
of this thesis. The results obtained from this work allowed formulating some 
general conclusions. 
Concerning the choice of the dataset, it should be as much homogeneous as 
possible, mostly in terms of biological data. These latter should come from the 
same testing protocol, ideally from the same operator. It is clearly difficult to obey 
to this rule when using large databases, in that they require collection, from the 
literature, of a large number of compounds usually coming from different authors. 
On the contrary, it is much easier to collect small datasets made up of 
homogeneous data.   129
Once a dataset has been selected, it has to be split into a TR and a TS. A number 
of selection criteria and algorithms have been proposed over the years in order to 
have a proper distribution of compounds between TR and TS and to optimize the 
predictive ability of the model under development. The results obtained from the 
protocols proposed in this thesis suggest that the TS should be first selected from 
a database of molecules showing the biological property of interest, working in 
parallel to the design of a virtual library that will be screened by using the model 
being developed. Subsequently, a suitable TR should be selected, so that it can 
reflect the chemical and biological characteristics of the TS. Not necessarily all the 
molecules, belonging to the initial database and left in after taking the TS out, 
have to be included in the TR, only the most representative ones must rather be 
considered. This rule allowed excluding both useless and redundant information 
from the TR. However, the TR should contain at least five data points, in order to 
have a proper correlation. 
All the compounds involved in the development of a model, both belonging to TR 
and TS, must then be represented in terms of molecular descriptors. A large 
number of descriptors is available, and many computer programs are able to 
quickly calculate them. The work presented here shows that 2D constitutional and 
topological descriptors gave good results, with the exception of a small number of 
cases in which the use of 3D geometry was strictly required for obtaining good fit 
of the experimental data. The use of constitutional and topological descriptors is 
advantageous in that they allow an easy and quick development of simple models, 
without the need for time consuming geometry optimizations. Moreover, most of 
these descriptors (especially the constitutional ones) provide an easier 
interpretation with respect to the more complex 3D descriptors. This facilitates the 
understanding of the structural features a molecule should have to improve the 
desired target property. 
Once descriptors have been calculated, correlation equation must be built on the 
basis of the most significant of them. The heuristic method provided by the 
program exploited in this thesis is useful to discard the less significant descriptors, 
and to have a quick estimate on the quality of correlation to be expected from the 
data, as well as to derive several reasonable regression models. It shows which 
descriptors are involved in the regression models obtained. The best ones must be 
selected on the basis of the related statistical parameters, and usually improved 
by a multi linear regression analysis. Here the model validation must take place,   130
t h a t  h a s  t o  b e  p e r f o r m e d  b y  l o o k i n g  a t  t h e  s t a t i s t i c a l  p a r a m e t e r s  c o m i n g  b o t h  
from the training and the test sets (respectively internal and external validation). 
The internal validation consisted in judging the R
2 and q
2 values calculated over 
the TR, while the external validation was accomplished by looking at R
2 value, R0
2 
(the correlation coefficient when the regression line is forced to pass through the 
origin of the axes), slope of the latter line and ratio (R
2-R0
2)/R
2, calculated over 
the TS. TR and TS are obviously disjoined from each other: from this the name of 
external validation originates, in opposition to the internal validation one, as this 
last is done on the same training set exploited for developing the model itself. 
After a QSAR model is obtained and properly validated, the identification of its 
applicability domain is required, that is the “chemical space” inside which it can be 
applied with high predictive power. In addition to some different criteria that are 
reported in the literature for describing the validity domain of a QSAR model, here 
this domain is referred to as the descriptor space. It is defined by the intersection 
of the range of the values (minimum to maximum) of each descriptor involved in 
a given model. Molecules with values of all descriptors comprised into the 
descriptor space will be reliably predicted, while molecules whose descriptors do 
not fall inside this range will be extrapolated, and their prediction will not be 
supported by statistics. In the study described in chapter 4 interpolation and 
extrapolation of compounds was carefully analyzed, both inside a same chemical 
class and between to different chemical classes. The results showed that being 
included inside the descriptor space is, of course, important in order to have a 
good prediction, but the chemical similarity still represents the most significant 
aspect. A low prediction error (low difference between calculated and 
experimental property value) is taken as a “good prediction” result. Nevertheless, 
it should be noted that extremely low errors do not have much sense, because 
they are lower that the experimental error itself. Since, as discussed in chapter 4, 
the same compound may show several pKi values when tested by different 
research groups, and the difference may also reach one logarithmic unit, it is 
reasonable to consider an error ≈ 1 acceptable (when using the pKi scale), 
especially for those compounds that were predicted by QSAR models developed 
starting from chemically diverse molecules (“extra-class” predictions). 
 
As a final conclusion, it can be pointed out that this work served to recognize the 
limits into which a QSAR model may be used in a reliable manner. The awareness   131
of these “boundaries” enriches the value of the contributions that QSAR 
techniques bring into the different steps of the drug discovery process.   132  133
Riassunto 
 
Il QSAR (relazioni quantitative struttura-attività) è definito come la correlazione 
dell’attività biologica (ecologica, tossicologica, farmacologica, ecc.) con la struttura 
dei composti chimici. Tale correlazione permette la predizione dei valori di attività 
biologica (ecologica, tossicologica, farmacologica, ecc.) di nuovi composti 
strutturalmente correlati. 
Molto tempo è passato dalla “scoperta” del QSAR e dalle sue prime applicazioni ed 
il numero di lavori di QSAR riportati in letteratura è enormemente cresciuto negli 
anni. Ciononostante, il QSAR lascia ancora aperti molti interrogativi che hanno 
costituito il punto di partenza di questo lavoro. 
Prima di tutto, è stata fatta un’analisi delle metodologie riportate in letteratura per 
capire come, in generale, viene costruito un modello QSAR. In breve, la procedura 
consiste nel prendere in considerazione un dataset di composti (più o meno 
omogenei dal punto di vista sia chimico che biologico), dividerlo in un training set 
(TR) ed un test set (TS) secondo metodi ed algoritmi diversi, sviluppare 
un’equazione di correlazione (cioè un modello QSAR) sulla base delle molecole 
scelte come TR (di solito con l’ausilio di software che calcolano e correlano 
descrittori molecolari), utilizzare il modello ottenuto per effettuare predizioni sul 
TS e validare il modello mediante determinati parametri statistici più o meno 
rigorosi. 
I concetti base che sono ancora in discussione variano ad esempio dai metodi di 
selezione dei descrittori ai criteri di correlazione, dagli algoritmi di selezione delle 
coppie TR/TS alla considerazione del dominio di applicabilità del modello QSAR, 
attraverso la validazione statistica del modello stesso. 
In questo lavoro, uno studio QSAR è stato considerato come una successione di 
diversi passaggi, ogni passaggio è stato accuratamente analizzato ed affrontato 
con un approccio rigoroso e razionale. Iniziando da quelli che sono i concetti tipici 
che fondano le basi del QSAR classico, lo scopo di questa tesi è stato quello di 
implementarli con l’uso di nuove strategie e nuove procedure, con l’obiettivo di 
sviluppare modelli QSAR “sicuri”, cioè dotati di una capacità predittiva affidabile.   134
Come argomento degli studi presentati qui sono stati scelti i ligandi per i recettori 
dell’adenosina, in particolare antagonisti, poiché possiedono molte potenzialità 
terapeutiche. Tali recettori sono infatti coinvolti nella protezione degli organi, 
compresi il cuore ed il cervello, da danno ischemico, mediano la nocicezione a 
livello spinale, a livello renale influenzano la produzione di urina e l’escrezione di 
sodio, sono coinvolti nella broncocostrizione (basti pensare all’antagonista 
teofillina, utilizzata come farmaco in alcuni c a s i  d i  a s m a )  e d  i n  a l c u n i  d i s t u r b i  
metabolici. 
Nei primi due capitoli di questa tesi vengono date informazioni di base e concetti 
fondamentali sulle due tematiche principali di questa tesi: le metodologie QSAR 
(Capitolo 1) ed il sistema adenosinico (Capitolo 2). I capitoli 3 e 4 descrivono 
invece in dettaglio il lavoro svolto. Il capitolo 5 presenta delle conclusioni generali 
ed una discussione che mette in evidenza l’importanza di avere la consapevolezza 
del “dominio” entro il quale un modello QSAR può essere applicato in modo sicuro. 
Soprattutto si è cercato di interpretare quelle che di solito sono intese come 
“limitazioni” intrinseche della metodologia QSAR in termini di “limiti”, o meglio di 
“confini”, entro i quali un modello dà predizioni affidabili. Questo enfatizza l’utilità  
del modello stesso e ne risulta l’importanza come strumento critico nei vari 
passaggi del processo di scoperta di un farmaco.   135
List of abbreviations 
 
2D Bi-dimensional 
3D Three-dimensional 
AB-MECA N6-4-amino-3-iodobenzyladenosine-5'-N-methyluronamide 
ADMET  Absorption, Distribution, Metabolism, Excretion, Toxicity 
AMP Adenosine  Monophosphate 
ATP Adenosine  Triphosphate 
cAMP  cyclic Adenosine Monophosphate 
cGMP   cyclic Guanosine Monophosphate 
CHO  Chinese Hamster Ovary 
CNS Central  Nervous  System 
DAG Diacylglycerol 
DPCPX 8-cyclopentyl-1,3-dipropylxanthine 
GDP Guanosine  Diphosphate 
GPCRs  G Protein Coupled Receptors 
GTP Guanosine  Triphosphate 
IP3   Inositol triphosphate 
MD   Molecular Dynamics simulations 
MLR Multi  Linear  Regression 
MM   Molecular Mechanics 
NECA N-ethylcarboxamidoadenosine 
PAPA-APEC 2-[4-[2-[2-((4-aminophenyl)methylcarbonylamino) 
ethylaminocarbonyl]ethyl]phenylethyl-amino]-5'-N-
ethylcarboxyamidoadenosine 
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